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S.M. TOUHIDUL ISLAM. Nonalcoholic Steatohepatitis: Role of Gut Microbiota is
Dependent on Lipopolysaccharide-Toll like Receptor-4 Axis. (Under the direction of
KENNETH D. CHAVIN)
Abstract
Hepatic steatosis is the hepatic manifestation of metabolic syndrome which is
increasingly becoming a health problem worldwide, especially in the western hemisphere.
Hepatic steatosis is benign, but long standing hepatic steatosis can lead to non-alcoholic
steatohepatitis (NASH).

NASH is a form of nonalcoholic fatty liver disease where

excessive fat accumulation in the liver leads to chronic inflammation of a patient without
any history of alcohol abuse. However, the mechanism underlying the progression of
hepatic steatosis to NASH is unclear. Role of gut microbiota in metabolic syndrome has
long been reported. Here, we hypothesized that gut microbiota plays an important role in
the modulation of NASH through the involvement of lipopolysaccharide (LPS)-toll-like
receptor-4 (TLR-4) pathway in dietary fat mediated hepatic steatosis.

To test this

hypothesis, germ free or broad-spectrum antibiotics-treated mice were fed high fat diet,
which resulted in decreased level of inflammation in their fatty liver compared to the
specific pathogen free control mice. This result demonstrated the involvement of gut
microbiota in mediating NASH.

To address the role of LPS-TLR-4 pathway, broad

spectrum antibiotics-treated mice fed high fat diet were injected i.p. with low dose LPS,
resulting in an increased level of inflammation in the liver which was decreased upon the
co-treatment with TAK-242, an inhibitor of TLR-4. To investigate the role of TLR-4expressing kupffer cells in mediating NASH, wild-type kupffer cells in the liver of wild-type
mice were replaced with TLR-4 KO kupffer cells by bone marrow transplantation, which
vi

resulted in a decreased level of inflammation in liver upon NASH induction. It was also
investigated whether the peroxisomal anti-oxidative function is altered in the livers of mice
fed high fat diet in a TLR-4 dependent manner. Indeed, the level and function of catalase,
the principal antioxidative enzyme in peroxisomes, was decreased in mice fed high fat
diet, which was reversed in TLR-4 KO mice fed high fat diet. This individual piece of data
demonstrated the role of TLR-4 pathway in modulating NASH through the alteration of
peroxisomal anti-oxidative function. In conclusion, this project established the role of gut
microbiota in modulating NASH which is dependent on LPS-TLR-4 pathway.
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Chapter 1
An Overview of Nonalcoholic Steatohepatitis and Gut Microbiota

1

Nonalcoholic fatty liver disease (NAFLD) is defined as a condition with excessive
fat accumulation and related complications in the liver of patients without any record of
alcoholism [1]. Fat accumulation in the liver can also result from alcohol abuse which is
called alcoholic fatty liver disease (AFLD) [2, 3]. NAFLD is an umbrella term which
encompasses simple steatosis to nonalcoholic steatohepatitis (NASH) [4].

Hepatic

steatosis refers to the normal accumulation of fat in the liver without or with minor
inflammation. Hepatic steatosis is benign, but long standing steatosis can lead to the
development of NASH which is the advanced stage of NAFLD showing clear indication
of chronic inflammation in the fatty liver [5, 6].
Epidemiology of NAFLD and NASH
NAFLD is a rapidly expanding health problem throughout the world. Currently, its
global incidence is approximately 25% [7]. Variations in the incidence rate for NAFLD
vary across the globe; the prevalence rate in Asia ranges from 5% to 18% and in Western
countries from 20% to 30% [8]. Of the individuals with NAFLD, approximately 7% to 30%
meet the clinical criteria for NASH [9]. Here in the USA, the prevalence rate for NAFLD
is 30%, with 25% of them satisfying the clinical definition of NASH. Thus, an overall
incidence rate for NASH within the US population is approximately 3-8% [10-13].
Risk of progression of NASH to end stage liver diseases
A major concern for individuals with NASH is the likelihood of their progression to
end stage liver diseases, that will ultimately require transplantation [14]. The potential of
NASH to progress into fibrosis and hepatocellular carcinoma is recognized. Alarmingly,
it has been projected that NASH is going to become the leading cause of liver related
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morbidity and mortality [15-18]. Although the patients with NASH are at greater risk,
individuals with simple steatosis and mild inflammation can also progress to fibrosis and
hepatocellular carcinoma [4, 5, 19-21]. Hepatic fibrosis is defined as an excessive
deposition of extracellular matrices, especially collagen, within the liver. While hepatic
fibrosis results in only minor clinical complications and/or hepatocyte dysfunction, it is
considered a predictor that the patient has a greater risk of developing cirrhosis [22].
Hepatocellular carcinoma is considered the fifth most common cancer and third leading
cause of cancer-related death in the United States [23]. Hepatitis C virus, alcohol-related
liver diseases, and hepatitis B virus have been implicated as the three leading causes of
hepatocellular carcinoma in the western world [24]. A role for NASH in this demographic
has been underestimated.

However, an increasing prevalence of NASH-related

hepatocellular carcinoma predicts that NASH is going to become the leading cause of
hepatocellular carcinoma in the Western countries in near future [10, 24]. Given the
epidemiological data with respect to NASH and its role in end stage liver diseases,
approaches to curb the transition from NAFLD to NASH is paramount if we wish to
improve the morbidity and mortality of patients afflicted with a steatotic liver.
From metabolic syndrome to NASH
The etiology of NASH is closely associated with metabolic syndrome [1, 4].
According to the World Health Organization, metabolic syndrome is a condition
characterized by multiple metabolic abnormalities including obesity, insulin resistance
and type-2 diabetes mellitus [25]. Diet and a sedentary life style have been implicated in
the development of metabolic syndrome. In the latter half of the 20th century with the
emergence of a sedentary ‘corporate professional life-style’ and ‘fast food culture’
3

(containing high fat, carbohydrate, and calories), Westerners are now considered to have
a greater risk for developing metabolic syndrome than the people in developing countries
where manual labor is still the norm for the bulk of the population [26-28].
Obesity is strongly associated with an increased risk of developing NAFLD.
Prevalence rate of NAFLD increases with an increase in body mass index [29, 30].
Incident rates of hepatic steatosis and NASH have been observed to occur respectively
at 95% and 20% in obese patients [9]. Fat deposition in the liver is directly correlated
with the accumulation of visceral adipose tissue. Mesenteric fat, a specific type of visceral
adipose tissue, is drained into the liver through portal circulation, leading to the deposition
of fat droplets causing hepatic steatosis [31, 32].
Insulin resistance is a common condition observed in individuals with metabolic
syndrome. Insulin resistance results in impaired glucose uptake and disposal, an increase
in de novo synthesis of fatty acids, and an inadequate level of free fatty acid oxidation
[33, 34]. Therefore, insulin resistance leads to the increased level of free fatty acids,
adding to the accumulation of fat in the liver [35].
As a mechanism, insulin action on the liver is coordinated between hepatocytes
and adipose tissue. In hepatocytes under a normal condition, insulin signaling pathways
result in a decreased expression of gluconeogenic enzymes, an inactivation of glycogen
synthase kinase 3β resulting in an activation of glycogen synthase, and improved rates
of glycolysis and mitochondrial oxidative phosphorylation. A decrease in the expression
of gluconeogenic enzymes and activation of glycogen synthase results in reduced free
glucose formation. Reduced level of free glucose indirectly inhibits the de novo synthesis
of fat by limiting the availability of precursor compounds [36, 37].
4

In adipose tissues under a normal condition, insulin signaling suppresses lipolysis
which in turn decreases the supply of free fatty acids and glycerol into the liver resulting
in a reduced formation of fat droplets. A reduced supply of glycerol into the liver inhibits
gluconeogenesis through the reduced conversion of glycerol to glucose [38-40].
In contrast to the insulin signaling in a normal condition, insulin resistance
constrains hepatic glycogen synthesis leading to an excess of free glucose. Insulin
resistance in adipose tissue impedes insulin-mediated suppression of lipolysis leading to
increased delivery of free fatty acids and glycerol into the liver [36, 41-45]. Insulin
resistance in the liver leads to an elevated level of free glucose. Elevated level of free
glucose is correlated with altered adipose lipid metabolism resulting in an increased
supply of free fatty acids and glycerol [46-50]. Therefore, insulin resistance mediates a
complex, reciprocal form of feedback between adipose tissue and the liver leading to
hepatic steatosis.
Type-2 diabetes mellitus (T2DM) is the most studied metabolic disorder with an
occurrence of insulin resistance and inability of pancreatic beta cells to produce sufficient
insulin to address the phenomenon of insulin resistance, [51]. The prevalence of NAFLD
has been linked to T2DM. In one study, it was reported that the prevalence of NAFLD in
obese patients with T2DM was 70% higher than in obese patients without T2DM [52].
These data taken collectively suggest that a close association exists between metabolic
syndrome and NAFLD [53]. Obesity, insulin resistance and T2DM are interrelated in
causing NAFLD, while insulin resistance plays the pivotal role in this inter-connection (Fig.
1.1).

5

Figure 1.1. Role of metabolic syndrome in the development of nonalcoholic fatty liver disease.
Excessive consumption of fat in concert with a sedentary lifestyle result in metabolic syndrome as
manifested by obesity, insulin resistance and type-2 diabetes mellitus. Insulin resistance plays the
pivotal role of metabolic syndrome in causing an increased level of free fatty acids in the liver through
their de novo synthesis in hepatocytes and enhanced adipose lipolysis resulting in nonalcoholic fatty
liver disease.
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A ‘Two-hit hypothesis’ to explain the pathogenesis of NASH
The pathogenesis of NASH has yet to be fully elucidated. Currently, it is explained
by a ‘two-hit hypothesis’ originally proposed by Day and James [54]. According to this
hypothesis, the first hit results from the accumulation of excessive fat leading to ‘hepatic
steatosis’. A liver is considered steatotic if it contains more than 5% to 10% fat [55].
Hepatic steatosis is phenotypically unremarkable, but a long-term steatosis can result in
the second hit caused by oxidative stress, dyslipidemia, mitochondrial dysfunction, an
altered cytokine milieu, immune infiltrations, and endoplasmic reticulum stress [56].
Subsequent to the second hit, the transition of the steatotic liver occurs from being
pathologically benign to a state where the organ is chronically inflamed [56].
Pro-inflammatory mediators of NASH
Oxidative stress, endoplasmic reticulum stress and hepatocyte apoptosis are
considered key pro-inflammatory mediators of NASH [56]. The concentration of free fatty
acids within hepatocytes is low in the normal condition. An increased influx of free fatty
acids into the hepatocytes initiates chronic inflammation within the liver. This increased
influx of free fatty acids can result from 1) the consumption of a diet rich in carbohydrates
or fat, 2) the lipolysis of stored fat, or 3) the de novo synthesis of fatty acids [56-58]. Such
an increase in the availability of free fatty acids within the hepatocytes results in an
increased fatty acid oxidation in mitochondrial and extra-mitochondrial sites leading to the
over-production of reactive oxygen species (ROS). An excess production of ROS creates
an imbalance with antioxidants, which in turn leads to oxidative stress and mitochondrial
dysfunction [59, 60] (Fig. 1.2).

7

Figure 1.2. Role of free fatty acids in the production of reactive oxygen species. Free fatty acids
can be directly transported into the liver from diet via chylomicrons. Free fatty acids can also be
delivered from the lipolysis of adipose tissues. They can also be synthesized de novo from diet-derived
carbohydrates. Free fatty acids are incorporated into triglycerides which are then accumulated into
lipid droplets leading to hepatic steatosis. Excess free fatty acids undergo fatty acid oxidation in
mitochondrial and extra-mitochondrial sites especially peroxisomes. Increased fatty acid oxidation in
hepatocytes leads to the elevated level of reactive oxygen species resulting in oxidative stress which
is the key initiator of steatohepatitis.
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The presence of excess free fatty acids within hepatocytes can also lead to an
overload of lipids in the endoplasmic reticulum (ER), resulting in ER dysfunction. ER
dysfunction results in the accumulation of unfolded and/or misfolded proteins manifested
as ER stress [61]. Mitochondrial dysfunction and ER stress culminate in the apoptosis of
hepatocytes, leading to the activation of hepatic innate cells and pro-inflammatory
immune infiltrates [59-62].
Gut microbiota and their contribution to human health
In addition to the consequences associated with free fatty acid-mediated oxidative
and ER stress, the role of other endogenous and exogenous mediators of NASH are of
interest. One area receiving significant attention is the role that gut microbiota plays in
the onset of NASH, but further investigation is required to have a better picture on the
mechanistic role of gut microbiota in mediating NASH. Bacterial cells living inside and
outside the human body outnumber the host eukaryotic cells [63]. The majority of these
microbes reside within the gastrointestinal tract due to favorable growth conditions and
the continuous influx of nutrients. It has been estimated that the total number of microbes
harbored in the gastrointestinal tract collectively make up to 100 trillion microbes which is
ten-fold higher than the human cells [64]. The unique gastro-intestinal niche confers
increased fitness and stability to the microbes through their continuous communication
and interactions with the host [65]. A tremendous number of studies have suggested that
the gut microbiota plays a critical role in the control and onset of human health and
disease. For instance, gut microbiota has an essential role in energy homeostasis and
nutrient recovery from ingested diets. The microbial genes from the collective microbial
community provide unique enzymes required for specific biochemical pathways [66, 67].
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These enzymes have essential roles in the metabolism of xenobiotics, undigested
carbohydrates and the biosynthesis of vitamins and cofactors essential to the host [67,
68]. Significantly, the gut microbiota generates short chain fatty acids that are used as
an energy source by the gut epithelial cells. These short chain fatty acids have an
important role in regulating gut motility and inflammation [69-71]. The gut microbiota also
serve an important role in providing a barrier to pathogens through competitive exclusion
and production of antimicrobial substances [67, 72-74].
Additionally, the gut microbiota has an essential role in the development of the
immune system of the host. It has been reported that there are an abnormal number of
immune cells and perturbations to the cytokine milieu in the lymphoid organs of germ free
mice [67, 75]. Depletion of gut microbiota in mice has been shown to result in the
depression of immunity and an abnormally reduced immune infiltrates in the gut [76]. Due
to a direct communication between the liver and gut, it is assumed that gut microbiota
may be responsible for the maintenance of intestinal health, which in turn may have an
impact on the overall function of the liver.
Dynamic composition of gut microbiota and metabolic syndrome
Compositional changes to the gut microbiota have been observed secondary to
environmental, immunological, dietary and/or nutritional alteration experienced by the
host. Such compositional changes have been associated with various host pathologies,
including metabolic syndrome [77-83]. Our understanding of the factors affecting the
composition of gut microbial community and how such changes can alter the risk of
metabolic disease in mammals was first attributed to studies conducted by Jeffrey Gordon
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and his group [84-86]. They showed that changes to the gut microbiota are secondary to
diet-induced obesity in mice. These changes significantly influence energy harvest from
diet, its utilization, and storage [86-88]. Apart from these studies in animal models,
changes to the gut microbiota in obese humans have been reported by Ley and
colleagues [89]. They showed that the proportions of Bacteroidetes to Firmicutes was
decreased in the gut of obese patients as compared to the lean controls. In concert with
obesity, dysbiosis was also observed in the metabolic syndrome manifested by T2D.
Reduced proportions of the phylum Firmicutes and class Clostridia in concert with higher
proportions of beta-proteobacteria were observed in patients with T2D compared to
healthy individuals [79]. Positive correlations have occurred with the concentration of
glucose observed in human plasma and the ratio of Bacteroidetes to Firmicutes as well
as the ratio of Bacteroides-Prevotella group to Clostridium coccoides-Eubactereium
rectale group [79]. These data suggest a potential association of T2D with compositional
changes to the microbial community within the human gut. Due to the close relationship
between metabolic syndrome and NASH, similar changes to the composition of gut
microbiota are anticipated in patients with NASH.
Gut microbiota bridges gut-liver axis
The term ‘gut-liver axis’ was first proposed by Volta and colleagues in 1978 [90].
Since then, a substantial number of studies have evaluated the association between the
gut and liver in concert with human health and diseases [91]. In a healthy state, the gut
epithelial layer selectively allows the entry of nutrients, ions and water across the gut
epithelial boundary while simultaneously excluding deleterious compounds and microbes.
The gut microbiota serves to protect the epithelial layer from pathogens through
11

competitive exclusion and production of pathogen specific antimicrobials. In addition to
providing a protective layer to exclude pathogens, the gut microbiota serves an important
role in maintaining a healthy epithelial barrier. The gut microbiota generates acetate,
propionate and butyrate which contribute to maintain a tight epithelial barrier [92-94].
Consequently, any change to the gut microbiota that alters the delicate balance to
epithelial nutrients may potentially compromise epithelial integrity, resulting in a condition
termed leaky gut [95]. During this abnormal circumstance, the gut epithelial layer will
demonstrate an impaired ability to regulate the entry of waste and other toxic components
into the circulation. A leaky gut has been observed in patients with NAFLD [95, 96]. All
gut-derived components crossing the epithelial barrier are drained into the liver through
portal circulation. Therefore, a leaky gut poses a potential threat to the liver by increasing
the supply of pro-inflammatory gut microbes-derived compounds into an organ that is
already susceptible to inflammation secondary to an excessive accumulation of fat [97,
98].
Gut microbiota induces pro-inflammatory pathways through the interaction with
toll-like receptors
Toll-like receptors are pattern recognition molecules expressed by a variety of
professional and non-professional immune cells. Toll receptor was originally identified in
Drosophila melanogaster as a molecule essential to determine the dorsal-ventral axis
orientation during embryogenesis [99].

Subsequently, human homologues were

discovered and named Toll-like receptors (TLRs) [100, 101]. The intracellular domains
of TLRs have similarity to the interleukin-1-receptor (IL-1R) known as Toll/Interleukin-1
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receptor (TIR) domain. The function of TIR domain is to recruit adaptor molecules that in
turn pass the signal upon the binding of ligands to the TLRs.
TLRs recognize microbe associated molecular patterns (MAMPs) and are
responsible for the induction of pro-inflammatory responses. In addition to microbial
components, TLRs can also recognize endogenous ligands known as danger associated
molecular patterns released from damaged tissue, infected tissue or dead cells. Upon
the binding of ligand to the extracellular domain of TLRs, adaptor molecules are recruited
to the cytoplasmic TIR domain resulting in a sequential activation of intracellular signaling
molecules called signal transduction. The consequence of signal transduction is the
activation of transcription factor nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB), which results in an expression of pro-inflammatory mediators such as
cytokines and chemokines.

In addition to activating the NF-κB pathway, mitogen

activated protein kinase cascades are also activated by the TLR-ligand interaction [100,
102, 103]. TLRs were initially considered only to induce anti-pathogen inflammatory
responses, but growing body of evidence indicates that activated TLRs are the underlying
cause for a number chronic inflammatory diseases (Table 1) [100, 103-112].
Potential role of low grade chronic endotoxemia in metabolic syndrome
The gut microbiota contains both Gram-positive and Gram-negative bacteria.
Lipopolysaccharide (LPS), also known as endotoxin, is a major outer membrane
constituent of Gram-negative bacteria. LPS is continuously produced and shed from
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Table 1. List of Toll-like receptors and their microbial/non-microbial ligands
TLRs

Microbe-derived ligands
Ligands

TLR-1/2/6

Nonmicrobial ligands

Diseases

Sources

Triacyl lipopeptides

Bacteria

Fatty acids

Atherosclerosis

Peptidoglycans

Gram-positive bacteria

Hyaluronan fragments

Phenol soluble modulin

Staphylococcus aureus

HMGB-1

Inflammatory
bowel disease
Asthma

Glycolipids

Treponema maltophilum

HSPs

Rheumatoid
arthritis

Atypical LPS

Non-entero bacteria

Phospholipomannan

Candida albicans

LPG

Leishmania major

Tc52

Trypanosoma cruzi

Diacyl lipopeptides

Mycoplasma

Lipoteichoic acid

Gram-positive bacteria

Zymosan

Saccharomyces cerevisiae

GPI anchor

Trypanosoma cruzi

Envelope protein

Measles virus

Synthetic dsRNA
(Poly(I:C)

Type 1 diabetes

Human cytomegalovirus
herpes simplex virus type I
TLR-3

TLR-4

dsRNA

Viral dsRNA

LPS

Gram-negative bacteria

Fatty acids

Rheumatoid
arthritis
Atherosclerosis

Mannan

Saccharomyces cerevisiae

Hyaluronan fragments

Multiple sclerosis

Candida albicans

HMGB-1

Asthma

Glucuronoxylomannan

Cryptococcus neoformans

HSPs

Rheumatoid
arthritis

F protein

Respiratory syncytial virus

Fibronectin fragments

Envelope protein

Mouse mammary tumor virus
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TLR-5

Flagellin

TLR-7/8

ssRNA

TLR-9

CpG DNA

Genomic DNA

Flagellated bacteria
Synthetic imidazoquinoline
derivatives
Bacteria

Immune complexes/dsDNA

Virus

HMGB-1

Systemic lupus
erythematosus
Type 1 diabetes

Babesia bovis

Multiple sclerosis

Trypanosoma cruzi

Inflammatory bowel
disease
Rheumatoid arthritis

Trypanosoma brucei

TLR-11

Inflammatory bowel
disease
Systemic lupus
erythematosus
Type 1 diabetes

Hemozoin

Plasmodium falciparum

Not determined

Uropathogenic bacteria

Profilin-like protein

Trypanosoma gondii

CpG DNA

Virus
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bacteria either through their lysis or growth [113, 114]. Although the presence of LPS is
restricted to the intestinal lumen [115], small amounts of LPS can pass through the
epithelial barrier and enter the circulation in healthy individuals [116]. While the presence
of LPS in circulation is normal, an increased concentration can result in chronic
endotoxemia. Thus, the role of an increased concentration of gut-derived LPS in blood
circulation is an important topic of investigation in relation to chronic inflammatory
diseases, in particular, the metabolic syndrome.
Inflammatory responses associated with acute endotoxemia, secondary to sepsis,
have revealed alterations to lipid metabolism [117, 118]. A lethal or sub-lethal dose of
endotoxin in mice leads to increased adipose lipolysis resulting in an elevated
concentration of circulating free fatty acids [119-121]. Despite an increased level of
circulating free fatty acids, fat accumulation in the liver is prevented due to the autophagy
induced by a lethal dose of endotoxin [120]. In contrast to acute endotoxemia, our
understanding of the pro-inflammatory consequences associated with a low
concentration of circulating LPS and its impact on lipid metabolism is still unclear.
Recently, Cani and colleagues have observed that a low concentration of endotoxin is
increased in obese (ob/ob) mice and in lean mice fed a high fat diet. They have shown
that a chronic elevation to the concentration of endotoxin through the infusion of low grade
LPS results in fat deposition in adipose tissue, which is in direct conflict to observations
associated with the animals exposed to acute endotoxemia [122, 123]. Moreover, plasma
levels of LPS have been reported to increase in patients with abdominal obesity
compared to the healthy controls, which is in line with the observations associated with
mice exposed to chronic endotoxemia [124].
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TLR-4 pathway is essential in the modulation of metabolic syndrome
LPS interacts with TLR-4 upon binding to CD14 to induce inflammation [125]. Cani
and colleagues have shown that CD14 knockout mice are partially protected from a high
fat diet-induced increase in adipose tissue and body weight [122, 123]. This study
suggested a role for the TLR-4 pathway in metabolic derangements in high fat dietmediated obesity in mice [123]. The TLR-4 pathway has also been linked to metabolic
syndrome in human patients. Creely et al. have shown that the expression level of TLR4 is higher in obese and in type-2 diabetes patients compared to healthy individuals [126].
Potential role of LPS-TLR-4 axis in NASH
In human, the liver is the first organ to encounter LPS delivered from the gut
microbial community. TLR-4 expressing Kupffer cells are a major and well characterized
target of LPS in the liver to execute the subsequent pro-inflammatory events [127, 128].
In comparison to healthy individuals, a slightly elevated level of serum endotoxin was
reported in NASH patients which led to investigations examining the potential role of low
dose LPS in driving inflammation in NASH in experimental models [129-132]. Indeed,
injection of subclinical dose of LPS in mice fed high fat diet or obese mice (ob/ob) resulted
in exacerbated hepatic inflammation indicating the role of chronic endotoxemia in causing
NASH [133]. Based on these reports, a comprehensive study to investigate the role of
LPS-TLR-4 axis in causing chronic inflammation in the fatty liver is needed. Therefore,
in this project, we attempted to establish the role of gut-derived LPS-TLR-4 pathway as
an actual risk factor to sustain a chronic inflammation during the pathogenesis of NASH.
We also attempted to employ the LPS-TLR-4 pathway as a potential target for therapeutic
intervention to stop the progression of NASH.
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Chapter 2
Materials and Methods
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Our initial objective was to investigate the global involvement of gut microbiota in
causing NASH. This objective was experimentally addressed by using specific pathogen
free and germ free mice.

We also conducted gut microbiota reconstitution

(conventionalization) experiment to test whether the restoration of gut microbiota in germ
free mice through fecal transfer from normal mice could impact the level of NASH. We
then intended to assess the role of LPS-TLR-4 pathway in mediating NASH by using wildtype and TLR-4 KO mice individually treated with broad-spectrum antibiotics, LPS, or
TLR-4 inhibitor. Bone marrow transplantation experiment was performed to investigate
the role of TLR-4-expressing kupffer cells in the modulation of NASH.

Following

euthanization, tissue samples were collected for subsequent analyses. In this chapter,
different experimental steps and methods used in this project have been described with
detailed information in a reproducible manner.
Animal experiments
Six-week-old male wild-type C57BL/6 mice were purchased from Jackson
Laboratories and maintained under specific pathogen free conditions. Six-week-old germ
free male C57BL/6 mice were bred and housed in flexible plastic gnotobiotic isolators
following a strict 12 h light cycle at the gnotobiotic animal research facility of the Medical
University of South Carolina.

Six-week-old toll-like receptor knock out (TLR-4 KO)

C57BL/6 male mice were purchased from Jackson Laboratories and maintained under
specific pathogen free conditions. After two weeks of equilibration on normal chow, the
now eight-week-old mice were placed either on an isocaloric control diet ((CD), TD.08810,
10% kcal from fat), a lard-based high fat diet ((LD), TD.06414, 60% kcal from fat, 63%
unsaturated) or a milk-based high fat diet ((MD), TD.09766, 60% kcal from fat, 61%
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saturated), purchased from Harlan Laboratories (IN, USA). Mice were housed at 22 °C
with 12 h light/dark cycle, fed special diets for 8, 16 or 32 weeks ad libitum and weighed
each week.

After 8, 16, or 32-weeks of feeding, they were euthanized whereupon the

liver were harvested and blood samples were collected. Whole livers were weighed with
portions of them processed for the isolation of total RNA and subsequent analysis for
specific proteins. The remaining fraction of the liver was fixed in 10% neutral buffered
formalin (Starplex Scientific Inc., Ontario, Canada) for 24 h at room temperature, with its
subsequent embedding into paraffin, sectioning, and histological/immunohistochemical
staining. All of the animal studies were reviewed and approved by the Medical University
of South Carolina’s Institutional Animal Care and Use Committee (IACUC).
For conventionalization (restoration of normal gut flora) experiment, gut microbiota
was reconstituted in six-week old germ free mice fed CD or MD by fecal transplantation
from specific pathogen free wild-type donor mice. Stool from donor mice were diluted in
saline (0.1g/mL) and gavaged into germ free animals on a weekly basis for a period of 16
weeks (200 µL per animal). The remaining stool solution was placed on the fur of the
animals. Part of soiled bedding was collected from the cages of stool donors and placed
into the cages of the conventionalized/recipient animals on the same weekly schedule.
Partial hepatectomy
Partial hepatectomy experiment was performed to investigate the role of dietary
fat-mediated NASH on hepatic regeneration. After 16 weeks of continuous feeding with
CD, LD or MD, C57BL/6 mice were anesthetized with isoflurane and subjected to a midventral laparotomy with approximately 70% of liver resection (left lateral and median lobes
hereafter referred to as resected lobes) [134]. Animals from individual diet interventional
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and control group were sacrificed 2 or 7 days post-hepatectomy. One hour prior to
sacrifice, a single dose of 5-bromo-2'-deoxyuridine (BrdU, Sigma-Aldrich, MO, USA) was
injected intraperitoneally at a dose of 50 mg/kg animal weight using a vehicle of 0.2%
pyrogen free phosphate buffered saline (Fig. 2.1). At the time of sacrifice, animals were
anesthetized with isoflurane and total blood was harvested from the right ventricle of the
heart. The remaining lobes of the liver, hereafter referred to as regenerated lobes, were
harvested. Both of the resected and regenerated lobes of the livers were weighed and
were processed for RNA, protein and histological analyses.
Treatment with broad-spectrum antibiotic, LPS and TLR-4 inhibitor
It was intended to investigate the role of LPS in causing NASH as a sole gutderived molecule present in the circulation. To ensure that chronic inflammation was not
induced by any gut-derived component other than LPS, gut microbiota was diminished by
the treatment of broad spectrum antibiotics followed by the chronic administration of low
dose LPS. Broad spectrum antibiotics-treated and LPS-injected mice were administered
with TLR-4 inhibitor to demonstrate the role of TLR-4 pathway in causing NASH. To
accomplish this experiment, specific pathogen free, C57BL/6 mice fed CD or MD for 16
weeks were treated with ampicillin (1 g/l: Sigma-Aldrich, USA), neomycin sulfate (1 g/l:
Sigma-Aldrich, USA), metronidazole (1 g/l: Sigma-Aldrich, USA) and vancomycin (500
mg/l: Sigma Aldrich, USA) ad libitum through the drinking water. During the last four
weeks of antibiotic treatment, the mice were injected intraperitoneally daily with 0.25
mg/kg body weight LPS (O55:B5, Sigma Aldrich, USA) or vehicle (0.9% saline). During
LPS injection, mice were also injected intraperitoneally three times per week with 3 mg/kg
body weight TAK-242 (Sigma Aldrich, USA) or vehicle (1% DMSO (Sigma Aldrich, USA)).
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Figure 2.1. Diagrammatic representation of hepatic regeneration experiment. Mice fed control diet or milkbased high fat diet for 16 weeks were subjected to partial hepatectomy. After 2 or 7-days of partial hepatectomy,
mice were injected with BrdU one hour prior euthanization. CD and MD indicate control diet and milk-based high
fat diet, respectively.
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TLR-4 KO mice fed CD or MD were injected with LPS using same protocol as mentioned
above (Figure 2.2A).
Bone marrow transplantation and depletion of kupffer cells
To investigate the role of TLR-4-expressing kupffer cells in mediating NASH, an
experiment was designed where kupffer cells in the livers of wild-type mice were
reconstituted with TLR-4 KO cells and kupffer cells in the livers of TLR-4 KO mice were
reconstituted with wild-type cells. To accomplish this experiment, 8x106 bone marrow
cells, obtained from wild-type or TLR-4 KO mice, were injected into tail vein of lethally
irradiated (11 Gy) TLR-4 KO or wild-type mice respectively. After 2 weeks of bone marrow
transplantation, mice were injected intravenously just once with 200 µl of 5 mg/mL of
liposomal chlodronate (Encapsula NanoSciences, USA). Injection of chlodronate
depleted the former kupffer cells resident in the liver and served to create an available
niche for the transplanted bone marrow-derived monocytes to settle as new kupffer cells.
After 10 weeks of chlodronate injection (during this 10 weeks mice were on regular chow
provided by the animal facility), both the wild-type and TLR-4 KO mice were fed CD or
MD for 16 weeks (Figure 2.2B) [135].
A question was raised whether the engrafted hematopoietic cells-derived
monocytes were actually settled as kupffer cells in the livers. Following experiment was
performed to answer this question using CD45.1 (donor) and CD45.2 (recipient) congenic
mice. 8x106 bone marrow cells isolated from CD45.1 donor mice were intravenously
injected into lethally irradiated (11 Gy) congenic CD45.2 recipient mice. Following 2
weeks after bone marrow cell injection, mice were injected intravenously just once with
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A

B

Figure 2.2. Diagrammatic representation of (A) antibiotic/LPS/TAK-242 treatment and (B) kupffer cell
reconstitution experiment. (A) Broad spectrum antibiotics-treated mice fed CD or MD for 16 weeks were injected with
LPS or administered with TAK-242 for last 4 weeks of experiment. (B) Lethally irradiated TLR-4 KO or wild-type mice
were transplanted with bone marrow isolated from wild-type or TLR-4 KO mice. After 2 weeks of bone marrow
transplantation, mice were injected with liposomal chlodronate. Following 10 weeks of liposomal chlodronate injection,
mice were fed control diet or milk-based high fat diet for 16 weeks. CD and MD indicate control diet and milk-based high
fat diet, respectively.
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chlodronate (200 µl of 5 mg/mL).

After 10 weeks of chlodronate injection, non-

parenchymal cells were isolated from the livers of chimeric and control mice and used for
flow cytometric analyses.
ALT and AST assays
Presence of alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) in the serum was determined as an indicator of NASH. After the collection of whole
blood through heart puncture, it was allowed to clot by leaving undisturbed at room
temperature for 15–30 min. The clot was removed by centrifuging at 1,000–2,000x g for
10 minutes at 4°C. Following centrifugation, the transparent yellowish liquid component
(serum) was immediately transferred into a clean polypropylene microcentrifuge tube and
stored at -20 °C [136]. Serum was assessed for the presence of ALT and AST using
standard kit protocols provided by the manufacturer (BioVision Inc., USA).
Endotoxin assays
In order to assess the concentration of circulating endotoxin, serum was collected
from the portal blood following the protocol used for serum collection from the whole blood
[136]. Portal serum was used to determine the concentration of LPS using the Pierce
Limulus Amebocyte Lysate (LAL) chromogenic endotoxin assay kit following standard
protocol provided by the manufacturer (Thermo Scientific, USA).
In order to assess the concentration of endotoxin resident in the fecal material of
the animals, 20 mg of fecal matter was collected from the cecum of each animal
whereupon it was placed into 50 mL PBS within a pyrogen-free tube. The material was
then sonicated at 20 KHz for 1 h on ice. Subsequent to sonication, the resulting material
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was centrifuged at 400 × g for 15 min. The upper 30 mL of the sonicate was collected,
sterilized by filtration through a 0.45-μm filter, re-filtered through a 0.22-μm filter, and
inactivated for 10 min at 70°C [137]. The LPS concentration present in the filtered
sonicate was determined using the Pierce Limulus Amebocyte Lysate (LAL) chromogenic
endotoxin assay kit following standard protocol provided by the manufacturer
(ThermoFisher Scientific, USA).
Liver histology and immunohistochemical staining
In order to assess the histopathological status of NAFLD, formalin fixed and
paraffin-embedded (FFPE) tissues were evaluated. The 5 µm FFPE sections were
stained with Hematoxylin and Eosin (Richard-Allan Scientific® Histology/Cytology
Reagents, ThermoFisher Scientific, USA) using the standard protocol provided by the
manufacturer. Slides were assessed for the extent to which each liver sample met the
criteria for NAFLD. This evaluation was performed by an experienced liver pathologist
using an established semi-quantitative schema [138-140]. In brief, NAFLD activity was
determined from the sum of the total steatosis observed, the extent with which lobular
inflammation was present and the level of hepatocellular ballooning. Levels of steatosis
were scored as a percent area of the field occupied by the empty spots secondary to the
release of fat droplets as a consequence of ethanol wash during the paraffin embedding.
Lobular inflammation was scored from the level of cellular infiltration and hepatocellular
ballooning was scored from the number of enlarged hepatocytes with rarefied cytoplasm
that achieved a size greater than 1.5 to 2 times the diameter of a normal cell [138-140].
In order to visualize the deposition of fat within the liver, liver tissues were
embedded in optimal cutting temperature (O.C.T) compound. The 5 µm O.C.T sections
26

were stained with oil red O (Sigma-Aldrich, USA) using the standard protocol provided by
the manufacturer [141]. Oil red O-stained O.C.T sections were visualized and imaged
using ZEISS Axiovert 200M inverted microscope equipped with a digital camera (20x
magnification).
In order to assess the level of collagen accumulation, 5 µm FFPE liver sections
were stained with picrosirius red. Briefly, FFPE sections were deparaffinized in xylene,
whereupon they were rehydrated by serially soaking in 100%, 95%, 90% and 0% ethanol
and then incubated in a solution of 0.1% Sirius red (Direct red 80, Sigma-Aldrich, USA)
and 1.3% saturated picric acid (Sigma-Aldrich, USA) for 1 hour. Subsequent to staining,
the sections were washed using a 0.5% acetic acid solution, whereupon they were
dehydrated by serially soaking in 0%, 90%, 95% and 100% ethanol and xylene.
Picrosirius red-stained sections were imaged using ZEISS Axiovert 200M inverted
microscope equipped with a digital camera (20x magnification).
Hepatocyte nuclear staining for BrdU was performed by using BrdU
immunohistochemistry kit essentially as described by the manufacturer (abcam, USA).
BrdU-incorporated hepatocytes were counted in high-power field of light microscope
using 20x magnification and expressed as a percentage of total hepatocytes (both BrdU
stained and non-stained).
The number of neutrophils present in each FFPE section was determined by
staining the sections with Leder stain (Napthol AS-D chloroacetate esterase, SigmaAldrich, USA). The number of infiltrating neutrophils was determined by counting the
number of Leder-positive cells encountered in each high-power field (20x magnification)
from each section evaluated.
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The number of macrophages present in each FFPE section was determined by
immunostaining for F-4/80. FFPE sections were incubated in 0.3% H2O2 for 30 min to
quench the activity of endogenous peroxidase followed by an incubation with primary
antibody (rat anti-mouse F4/80, clone BM8, Biolegend, USA) and secondary antibody
using Vectastain ABC kit (Vector Laboratories, USA) following the standard protocols
provided by the manufacturers. The percentage of macrophage infiltration was
determined as the number of positively stained macrophages against the total number of
cells present in each high power field (20x magnification) per section [142].
In order to do fluorescence immunohistochemistry, FFPE sections were boiled in
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for 30 min for
antigen retrieval followed by the blocking with 5% BAS for 30 min at room temperature,
overnight incubation with the primary antibody at 4°C, 1.5 hour incubation with secondary
antibody, and DAPI staining following standard protocol (abcam, USA).
Quantitative real time reverse transcriptase polymerase chain reaction (RT-PCR)
Expression levels of different NASH-indicative genes were determined by using
RT-PCR. Total RNA was isolated from 20-50 mg liver tissue using Trizol (Ambion, USA)
according to the manufacturer’s instructions. The concentration of RNA recovered was
determined by Nanodrop Spectrophotometer (ThermoFisher Scientific, USA). The quality
of RNA was assured by determining the ratio of absorbance at 260 nm and 280 nm. A
ratio of absorbance at 260 nm and 280 nm higher than 2.0 confirmed the purity of RNA
samples [143]. The concentrations of RNA between samples were equalized through
dilution using sterile, RNase free water.
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RT-PCR was accomplished by taking 500 ng of RNA, subjecting it to reverse
transcription with subsequent amplification of the DNA template using LightCycler 480
instrument (Roche, USA) using the TaqMan Fast Virus 1-step PCR master mix (Applied
Biosystems, USA) and TaqMan-FAM-MGB primers/probes (Applied Biosystems, USA) in
a final reaction volume of 20 µL using the following thermocycling profile. 1) Reverse
transcription at 50°C for 5 min; 2) inactivation of the reverse transcriptase by exposing the
reaction to 95°C for 20 sec; and 3) amplification of newly transcribed DNA template with
40 successive cycles at 60°C for 30 seconds followed by denaturation at 95°C. Genespecific probe information are provided in Table 2.1. The expression level of a given gene
was calculated as a fold difference in relative to the normalized expression level
housekeeping gene HPRT1 using the comparative ∆∆Ct method [144].
Western blot analysis
Differences in the expression level of different NASH-associated proteins in the
liver were assessed by using Western blot analysis.

In order to prepare tissue

homogenate, 50 mg of liver tissue was homogenized in 200 µL of RIPA buffer (25 mM
Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS and 5%
mammalian proteinase inhibitor) (Sigma-Aldrich, USA) [145]. Protein concentration in the
tissue homogenate was determined by following the instruction of BCA assay kit (Pierce,
USA). Then, 5 µg of protein samples were run on 4-12% NuPage polyacrylamide gels
(Life Technologies, USA) and transferred to nitrocellulose membrane (ThermoFisher
Scientific, USA). After blocking with TBS-T (Sigma-Aldrich, USA) containing 5% milk for
30 min, blots were incubated overnight at 4°C with the primary antibody diluted in TBS-T
containing 5% milk [146]. The blots were then washed with TBS-T, incubated with
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peroxidase-conjugated secondary antibody diluted in TBS-T containing 5% milk for 1.5 hr
at room temperature (information about the antibodies used in Western blot analysis are
provided in Table 2.2). After 3×5 min washing with TBS-T, blots were

Table 2.1. List of probes used for RT-PCR
Probe
Gene bank address

Company

HPRT

Mm00446968_m1

ThermoFisher

TNF-α

Mm00443258_m1

ThermoFisher

IL-1β

Mm00434228_m1

ThermoFisher

CCL-2

Mm00441242_m1

ThermoFisher

TGF-β

Mm00441724_m1

ThermoFisher

α-SMA

Mm01546133_m1

ThermoFisher

Col-1a

Mm00801666_g1

ThermoFisher

Table 2.2. List of antibodies used for immunoblot and immunofluorescence staining
Antibody

Dilution

Company

Clone/RRID

Rabbit anti-PARP Ab

1:1000

Cell Signaling

46D11

Goat anti-rabbit HRP-linked secondary Ab

1:2000

Cell Signaling

7074S

Mouse anti-catalase monoclonal Ab

1:4000

ThermoFisher

12C2DB9

Mouse anti-GAPDH Ab

1:4000

Ambion

6C5

Goat anti-mouse HRP-liked secondary Ab

1:4000

ThermoFisher

AB_2533947

Alexa Fluor 488 Goat anti-Rabbit IgG

1:1000

Invirogen

AB_143165

Rabbit polyclonal to Catalase

1:500

abcam

ab16731

Rabbit polyclonal to PMP70

1:500

abacm

ab3421
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incubated with freshly prepared SuperSignal West Femto Maximum Sensitivity Substrate
(Thermo Scientific, USA) for 1-5 min and imaged using luminescent image analyzer
(Image Quant LAS 4000, GE Healthcare Life Sciences, PA, USA).

Densitometry

analyses were performed using Image J software (National Institutes of Health, USA).
Catalase activity assay
Catalase activity present in liver homogenates was assessed in order to provide
an approximation of the alteration to peroxisomal anti-oxidative function. 50 mg tissue
homogenates were prepared and used for catalase activity assay using standard protocol
of catalase activity colorimetric/fluorometric assay kit (BioVison Inc., USA).
16S rRNA analyses
To investigate the impact of change of diet on gut microbiota, diet-conversion
experiment was performed. In this experiment, six-week-old mice were fed milk diet (MD)
for 16 weeks. Then, the diet was switched from MD to control diet (CD) for another 16
weeks. Following euthanization, mice abdomen was opened and stool pellets were
collected from the severed distal ilium using blade and tweezers. Collected stool was
snap frozen and stored at -80°C. Analysis of the 16S bacterial DNA from was carried out
at the Microbiome Core Facility of the University of North Carolina. DNA was extracted
from samples using the Epicentre® MasterPure Complete DNA Purification Kit (Illumina,
Inc.) and bacterial DNA was amplified and sequenced by the Illumina MiSeq system. 16S
rDNA amplicons was purified and quantified on an Invitrogen Qubit system and assessed
on an Agilent Bioanalyzer. Following quality filtering, sequences was de-multiplexed and
trimmed using QIIME open source software (http://qiime.org). Downstream alignment of
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QIIME processed sequences; identification of open taxonomic units (OTUs), clustering,
and phylogenetic analysis was conducted using the Phylosift open source software
package (http://phylosift.wordpress.com). Statistical analyses of community diversity
within and amongst experimental groups included Principal Components Analysis,
Squash Clustering, and Kantorovich-Rubinstein distance (akin to weighed UniFrac).
Isolation of kupffer cells and flow cytometric analyses
In order to do the flow cytometric analysis, kupffer cells were isolated from the liver
using the following protocol [147, 148]. Livers were perfused with 5 ml Hank’s balanced
salt solution (HBSS), followed by 12 ml digestion buffer (HBSS containing 0.5 mg/ml type
VI collagenase (Sigma-Aldrich) and 10 mg/ml DNase I (Roche)).

The livers were

removed, minced and incubated in digestion buffer at 37°C for 20 min with subsequent
passage through a 40 mm cell strainer. Parenchymal cells were removed by low speed
centrifugation at 50xg for 2 min. The supernatant enriched in non-parenchymal cells was
centrifuged at 800xg for 30 min through a 25% (v/v) percoll gradient at room temperature
with no brake. The pellets of the gradient containing kupffer cells were washed and used
for flow cytometric staining. 0.5–5 × 106 cells in 200 µl stain buffer plus Fc blocker (1:50)
in FACS tubes were incubated on ice for 20 min.

Then, surface marker-specific

conjugated antibodies or unconjugated primary antibodies (5 µl/106 cells) (Table 2.3) were
added and incubated for 30 min on ice in the dark. Then, cells were washed and
incubated with conjugated secondary antibodies (5 µl/106 cells) for 30 min on ice in the
dark. After incubation, cells were again washed and treated with propidium Iodide at the
concentration of 1 µg/ml. Then, the cells were run through LSR II flow cytometer (BD,
Bioscience) and analyzed using FlowJo software (FlowJo LLC).
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Table 2.3. List of antibodies used for flow cytometric analyses
Antibodies

Target cells

Company

Clone

Ly6G BV650

BD Biosciences

1A8

BD Biosciences

E50-2440

Ly6C BV421

Granulocytes, Neutrophil,
Eosinophil
Granulocytes, Neutrophil,
Eosinophil
Monocytes

BD Biosciences

AL-21

F4/80-Biotin

Kupffer cells

Biolegend

BM8

CD45.1 PECy7

Donor cells

BD Biosciences

A20

CD45.2 PerCP-Cy5.5

Recipient cells

BD Biosciences

104

Streptavidin-QDot650

Kupffer cells

ThermoFisher

-

Fc blocker

Fc receptor blocker

BD Biosciences

2.4G2

Propidium iodide

Dead cells

ThermoFisher

-

SiglecF BV650

Statistical analyses
All values were expressed as mean ± standard error of the mean. Statistical
significance was chosen a priori as α ≤ 0.05. Two groups of data were analyzed using
non-parametric statistics employing the Mann-Whitney U test to analyze single, unpaired
comparisons of normally distributed data sets.

Multiple groups of data were analyzed

using nonparametric one way ANOVA. Statistical analyses were performed using
GraphPad PRISM version 7.
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Chapter 3
Dietary Model of NASH: Pathology of NASH Develops at a Higher
Level in Animals Fed a Diet Rich in Saturated Fats

34

Summary
In order to study NASH, it is essential to have an animal model that faithfully mimics
the pathology and symptoms of the disease observed in humans. Of the different NASH
models available, those employing a high fat diet to facilitate the development of NASH
better represent the symptoms and pathological indicators of NASH than those relying on
genetic perturbation or other forms of dietary intervention.

Both unsaturated and

saturated fats result in hepatic steatosis followed by the development of NASH. However,
their comparative role in triggering inflammation in the fatty liver is still unclear. Reports
state that saturated fatty acids are more toxic than unsaturated fatty acids. Therefore, we
hypothesized that mice fed a saturated high fat diet would manifest higher level of
inflammation in the liver compared to mice fed an unsaturated high fat diet. To test this
hypothesis, 6-8 week-old mice were fed three distinct diets: a low fat control diet ((CD),
10% calories from fat), a lard-based unsaturated high fat diet ((LD), 60% calories from
unsaturated fat), and a milk-based saturated high fat diet ((MD), 60% calories from
saturated fat). The mice were fed for a period of 8, 16 or 32 weeks in order to assess the
time at which NASH was clinically more apparent.

Serum and liver tissues were

examined for inflammation-indicative markers, which demonstrated an elevated level of
NASH in mice fed LD or MD compared to the mice fed CD at week 16 and 32. At week
8, none of the mice fed LD or MD developed significant level of NASH as compared to
the mice fed CD. As a comparison between LD and MD, mice fed MD exhibited a higher
trend of NASH than the mice fed LD at week 16 and 32. In conclusion, while both types
of high fat diets can induce NASH in mice after 16 or 32 weeks of feeding, saturated high
fat diet is more efficient in inducing inflammation than unsaturated high fat diet.
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Introduction
In order to develop a strategy for the successful management of NASH, we first
need to understand the pathogenesis of the disease. To this end, it is essential to be able
to follow the progression of disease in human patients or experimental models [149].
Although human patients are the first choice for studying NASH, it is subjected to some
major limitations. Because of the long period of time, sometimes even decades, required
to develop NASH in humans, and given the ethical restrictions of administering drugs to
and collecting liver tissues from NASH patients, it is extremely important to have an
experimental model faithfully mimicking NASH [150]. A suitable animal model of NASH
can help researchers understand the pathology of NASH and test the effects of different
therapeutic products [150, 151]. An appropriate animal model of NASH should correctly
reflect the histological lesions (fat accumulation, immune infiltration, fibrosis) and
pathophysiological indicators observed in human patients [151]. Currently both genetic
and dietary models of NASH are available. Because none of these models perfectly
mimics the histopathology or pathophysiology of NASH in humans, they are only useful
for investigating certain aspects of the disease. Available genetic models of NASH are
sterol regulatory element binding protein (SREBP)-1c transgenic mice, leptin deficient
ob/ob mice, leptin receptor deficient db/db mice, phosphatase and tensin homologue
deleted on chromosome 10 (PTEN) null mice, agouti gene mice, peroxisome proliferatoractivated receptor-α (PPAR-α) knockout mice, acyl-coenzyme A oxidase (AOX) null mice
and methionine adenosyltransferase-1A (MAT-1A) null mice [53, 150, 151]. One major
limitation of these genetic models of NASH is that none of the genetic perturbations are
present in the human patients. Moreover, some of these models (ob/ob mice, db/db mice
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and agouti mice) do not progress from steatosis to steatohepatitis spontaneously. They
require an additional insult ( e.g. feeding with special diet) to induce steatohepatitis [150].
As compared to the genetic models, dietary models have a higher relevance to NASH in
humans, because they develop the disease only through the consumption of special diets
without the need for genetic alterations. Currently available such special diets are
methionine choline deficient diet, diet containing cholesterol and cholate, fructose
enriched diet, and high fat diet [150, 151]. An important limitation of these dietary models
is that none of these diets represents regular human diet. A Combination of genetic
perturbation and dietary challenge can also develop the histopathological and
pathophysiological features of NASH [152-156]. Of these available genetic and dietary
models, high fat diet-mediated NASH is clinically more relevant due to its similarity to the
‘western diet’ in having high fat content.
A typical ‘Western diet’ contains calories from both unsaturated and saturated fats
[157]. A Pro-inflammatory role for saturated fats has been demonstrated in different
diseases [158-163]. Diets containing high amount of saturated fats have been linked with
coronary heart disease, insulin resistance, metabolic syndrome and diabetes [158].
Saturated high fat diet causes higher incidence of colitis in genetically susceptible mice
compared to the polyunsaturated high fat diet [159].

Role of saturated fats in the

progression of NAFLD has also been shown in numerous reports [160-163]. Saturated
fats mediate NAFLD through the accumulation of elevated level of reactive oxygen
species, endoplasmic reticulum stress and lipotoxicity [164].

Due to these pro-

inflammatory roles of saturated fat over unsaturated fat, it was investigated in this study
whether a milk-based saturated high fat diet (MD) is more efficient in inducing NASH
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compared to the lard-based unsaturated high fat diet (LD). It was reported that feeding
of mice with high fat diet for 8-12 weeks could induce NASH [133, 142], but no previous
study had demonstrated the impact of different feeding periods on NASH development.
Therefore, an important aspect of this study was to identify an optimum time (8, 16 or 32
weeks) for feeding mice so that the maximum level of inflammation in the fatty liver is
ensured.
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Results
Both LD and MD led to the development of hepatic steatosis at week 16 and 32,
while MD showed a non-significant higher trend than LD
Both of the mice fed LD or MD led to the development of hepatic steatosis at week
16 and 32 (Figure 3.1). Representative images of H&E and ORO stained liver sections
clearly displayed massive fat accumulation in the livers of mice fed LD or MD at week 16
(Figure 3.1A). Clinical scores of steatosis reflected higher levels of fat accumulation in
the livers of mice fed LD or MD compared to the mice fed CD both at week 16 and 32
(Figure 3.1B). At week 8, there was only a higher trend of fat accumulation in the livers
of mice LD or MD compared to the mice fed CD. When compared between LD and MD,
mice fed MD showed higher trends of steatosis score compared to the mice fed LD at
week 16 and 32.
Both LD and MD led to the development of chronic inflammation in the fatty liver,
while MD displayed a non-significant higher trend than LD at week 16 and 32
Both of the mice fed LD or MD showed higher expression of TNF-α, IL-1β and
CCL-2 , higher levels of NAFLD score, higher infiltration of neutrophils and macrophages,
and elevated serum activities of ALT and AST compared to the mice fed CD at week 16
and 32 (Figure 3.2A-H). At week 8, both of the mice fed LD or MD showed only higher
trend of NASH indicators compared to the mice fed CD. When compared between LD
and MD, mice fed MD showed higher trend of these NASH-indicative parameters
compared to the mice fed LD at week 16 or 32.
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A

B

Steatosis score

Figure 3.1. Consumption of unsaturated or saturated high fat diet led to hepatic steatosis both at week 16 and
32. Mice fed either a lard-based unsaturated or milk-based saturated high fat diet for 16 or 32 weeks responded with fat
accumulation in their livers as shown by the representative images of (A) H&E and ORO stained liver sections (at 16
weeks) and (B) clinical score of steatosis. CD, LD, and MD denote control diet, lard-based unsaturated and milk-based
saturated high fat diet, respectively. # indicates significant difference between CD and LD when P<0.05, $ indicates
significant difference between CD and MD when P<0.05; data are expressed as mean±SEM; n=6-8 (Man-Whitney test).
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Figure 3.2. Feeding with unsaturated or saturated high fat diet led to the development of NASH both at week
16 and 32. Mice fed either a lard-based unsaturated or milk-based saturated high fat diet for 16 or 32 weeks resulted
in the development of NASH as indicated by the higher expression of (A) TNF-α, (B) IL-1β and (C) CCL-2, (D)
higher levels of NAFLD score, higher infiltration of (E) neutrophil and (F) macrophages and higher serum activities
of (G) ALT and (H) AST. CD, LD, and MD denote control diet, lard-based unsaturated and milk-based saturated
high fat diet, respectively. # indicates significant difference between CD and LD when P<0.05, $ indicates significant
difference between CD and MD when P<0.05, * indicates significant difference between LD and MD when P<0.05;
data are expressed as mean±SEM; n=6-8 (Man-Whitney test).
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Mice fed LD or MD both showed the indication of fibrosis in the fatty liver, yet
feeding with MD showed a higher level of expression of TGF-β than feeding with
LD
Mice fed LD or MD both showed higher levels of indicators of fibrosis in their livers
compared to the mice fed CD. Representative images of picrosirius red stained liver
sections of mice fed LD or MD at week 16 displayed higher levels of collagen
accumulation compared to the mice fed CD (Figure 3.3A). Mice fed LD or MD showed
higher levels of expression Col-1a and TGF-β in their livers compared to the mice fed CD
at week 16 and 32 (Figure 3.3B-C). Mice fed MD showed significantly higher level of
expression of TGF-β compared to the mice fed LD at week 16 (Figure 3.3B-C).
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Figure 3.3. Mice fed unsaturated or saturated high fat diet showed the indication of fibrosis both at week 16
and 32. Mice fed either a lard-based unsaturated or milk-based saturated high fat diet for 16 or 32 weeks resulted in
the accumulation of collagen in their livers as shown by the representative images of (A) picrosirius red stained liver
sections (at 16 weeks) and higher levels of expression of (B) col-1a and (C) TGF-β. CD, LD, and MD denote control
diet, lard-based unsaturated and milk-based saturated high fat diet, respectively. # indicates significant difference
between CD and LD when P<0.05, $ indicates significant difference between CD and MD when P<0.05, * indicates
significant difference, between LD and MD when P<0.05; data are expressed as mean±SEM; n=6-8 (Man-Whitney
test).
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Discussion
To investigate the pathogenesis of NASH, it is essential to have a model
appropriately mimicking the disease in human. In compared to the genetic models,
induction of NASH in obesogenic high fat diet-fed mice does not associate any genetic
defects or pathological feature not observed in clinical paradigm of NASH [150, 165, 166].
Therefore, a high fat diet model is considered as the clinically most relevant model of
NASH. Although high fat diets are widely used for NASH research, different pathological
aspects of NASH in humans are poorly reflected in this model. For instance, fibrosis is a
very common phenomenon in patients with NASH. Around 40% of NASH patients have
advanced stages of fibrosis in their livers [167]. However, mice fed a high fat diet develop
a very poor level of fibrosis, which is a major obstacle to study fibrosis in NASH using this
model [168]. In the current study, mice fed a high fat diet for 16 or 32 weeks resulted in
increased expression of col-1a and a pro-fibrotic cytokine TGF-β, and higher
accumulation of collagen indicating an a progression to fibrosis. Other indicators of
NASH, e.g. higher expression of pro-inflammatory cytokines, immune infiltrations, and
hepatocyte damage as reflected in higher serum ALT/AST level, were clearly manifested
in mice fed either an unsaturated or saturated high fat diet.
When compared the mice fed LD and MD, we detected a higher trend (although
statistically non-significant) of NASH-indicative markers in mice fed MD compared to the
mice fed LD at week 16. Notably, differences between the mice fed LD and MD became
less prominent at week 32. This might be due to the maximum impacts of either types of
diets on NASH, resulting in a level of saturation. The higher level of inflammation in the
livers of mice fed MD compared to the mice fed LD could be attributed to the higher
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amount of saturated fatty acids in MD [164, 169]. Pro-inflammatory mechanisms of
saturated fatty acids have been explained in different reports. Excess free fatty acids,
released from the lipolysis of subcutaneous and visceral adipose tissues, enter the liver.
Upon entering the liver, free fatty acids are disposed through β-oxidation, triglyceride, and
phospholipid synthesis. Mitochondrial β-oxidation leads to the gradual break down of the
fatty acids into two-carbon acetyl-coA which enters the tricarboxylic acid cycle. Excess
free fatty acids can also be disposed by esterification into triglycerides and phospholipids.
In the case of excess level of saturated free fatty acids, higher amounts of saturated fatty
acids are channeled to the esterification of phospholipids than to the esterification of
triglycerides or β-oxidation. Abnormal saturation of phospholipids can compromise the
membrane fluidity of endoplasmic reticulum leading to impaired protein folding and
trafficking which eventually results in endoplasmic reticulum stress through unfolded
protein signaling pathway [164, 170-172].
In compared to unsaturated fatty acids, saturated fatty acids are used for the
synthesis of toxic molecules. For instance, condensation of palmitate (16:0 saturated
fatty acid) and serine leads to the synthesis of ceramide, a toxic lipid molecule [173, 174].
Accumulation of ceramides in mitochondrial membrane results in an increased
permeability resulting in cytochrome c release, that eventually induces apoptosis [175].
Increased accumulation of ceramides in sphingolipid-rich lipid rafts of plasma membrane
drives the coalescence of lipid rafts into larger platforms, which facilitate the apoptotic
signaling by clustering membrane receptors and signaling molecules [176-179].
Saturated fatty acid-derived ceramide can also directly interact with the pro-enzyme
cathepsin D and induce its autolytic cleavage releasing the active components of
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cathepsin D, which mediates the cleavage and activation of pro-apoptotic Bcl-2 family
member Bid [180, 181].
Another important difference between unsaturated and saturated fatty acids is that
saturated fatty acids can induce inflammation through the direct interaction with, and
activation of TLR-4 [182-184]. Saturated fatty acids are essential component of
endotoxins. Human TLR-4 can sense only the endotoxins containing lipid-A portion
accylated with six saturated fatty acids (usually 12-16 carbons in length). It has been
shown that replacement of these saturated fatty acids with monounsaturated or
polyunsaturated fatty acids halts the pro-inflammatory effects of lipopolysaccharides [184,
185]. From the inflammatory point of view, saturated fatty acids can also induce the
expression of cyclooxygenase-2 through an NF-κB-dependent activation of macrophages
[183]. Cyclooxygenase enzymes catalyze the synthesis of prostaglandins and
thromboxanes, which are important mediators of different aspects of inflammation, e.g.
vasodilation, leukocyte migration etc. [184, 186-188].

Therefore, it is possible that

saturated fatty acids leads to the production of these mediators inducing pro-inflammatory
immune infiltration in the fatty liver.
Both LD and MD contain unsaturated and saturated fatty acids of different lengths
and saturation types/levels, but the levels of saturated fatty acids, particularly the toxic
ones like palmitic, stearic, and lauric acids, are higher in MD compared to LD [184, 189191]. Because of the higher pro-inflammatory roles of saturated fatty acids over
unsaturated fatty acids, as reflected in the higher trends of NASH-indicative markers in
mice fed MD versus the mice fed LD, we chose MD to induce NASH in mice for the
experiments reported herein.
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Chapter 4
High Fat Diet-mediated Nonalcoholic Steatohepatitis Impairs Hepatic
Regeneration Following Partial Hepatectomy
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Summary
Although surgical resection of part of the liver (partial hepatectomy) is a wellrecognized treatment option for hepatocellular carcinoma, pre-existing pathological
abnormalities originating from fat-rich diet mediated steatosis can alter the postoperative
outcomes. Despite the well-established effect of NASH in liver, little is known about the
impact of fat-rich diet on the ability of the liver to regenerate. In this study, we investigated
the impact of both saturated and unsaturated fat-rich diet on liver regeneration following
partial hepatectomy in C57BL/6 mice. Six week-old mice were fed control diet (CD), Lardbased unsaturated fat-rich diet (LD) or milk-based saturated fat-rich diet (MD) for 16
weeks. Partial hepatectomy (70% of the liver) was carried out at 16 weeks. At day 2 and
at day 7 post partial hepatectomy, mice were injected with 5-bromo-2'-deoxyuridine
(BrdU) i.p., one hour prior to euthanization to analyze hepatic regeneration. Samples
were collected from the resected and regenerated liver and examined for inflammationindicative markers and histological analyses.

Mice fed LD or MD exhibited higher

nonalcoholic fatty liver disease (NAFLD) score, levels of inflammatory cytokines, and
infiltration of neutrophil and macrophage in both resected and regenerated livers
compared to mice fed CD. Mice fed LD or MD resulted in decreased BrdU incorporation
in their resected and regenerated livers compared to the mice fed CD. Our study
demonstrated the impaired hepatic regeneration post partial hepatectomy of mice fed LD
or MD compared to that of mice fed CD. Importantly, mice fed MD demonstrated reduced
regeneration compared to the mice fed LD.

Collectively, this study illustrates the

significance of fat and type of fat type in impairing hepatic regeneration following partial
hepatectomy.
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Introduction
The liver has a unique ability to regenerate, even when mature, following a toxic
insult or partial hepatectomy (PHx) [192, 193]. In spite of its substantial metabolic role,
the liver is a quiescent organ in terms of hepatocyte proliferation. Although hepatocytes
undergo a very low rate of proliferation under normal conditions, they can reach a
dramatically high proliferation rate within the acinar architecture of the remnant liver
following a surgical resection leading to total recovery of the organ within 2-6 weeks [194].
As a result of this ability to regenerate, surgical resection is often considered a viable
treatment option for end stage liver diseases including liver cirrhosis or hepatocellular
carcinoma [195, 196]. Although surgical resection of part of the liver (PHx) is considered
a viable treatment option for patients with end-stage liver diseases, post-resection
regeneration capacity is of major concern. Therefore, it is important to have a clear
understanding of the effect that pre-existing steatosis or NASH have on the hepatic
regeneration following PHx.
Although the role of a high fat diet in causing an impairment of hepatic regeneration
following PHx in mice has been reported [142], it is still not clear how differently NASH,
induced by either unsaturated or saturated high fat diet, may impact hepatic regeneration
following PHx. This study assessed the ability of a lard-based unsaturated high fat diet
(LD) and a milk-based, saturated fat rich diet (MD) in conferring an impairment to the
livers of mice to regenerate following a PHx. The findings here may influence the decision
to perform and/or post-operative management of patients being considered for PHx
surgery.
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Results
Mice fed LD or MD led to the development of NASH in both resected and
regenerated livers
Levels of expression of TNF-α, IL-1β, TGF-β, and CCL-2 were increased in both
of the resected and regenerated livers of mice fed either LD or MD compared to the mice
fed CD (Figure 4.1A-D). Hepatic infiltrations of neutrophils and F4/80+ macrophages were
increased in both of the resected and regenerated livers of mice fed either LD or MD
compared to the mice fed CD (Figure 4.1E-F). Each of these NASH indicators clearly
demonstrated the development of NASH in the resected and regenerated livers of mice
fed LD or MD. Noticeably, resected and regenerated livers of mice fed the MD trended
to exhibit higher levels of expression of inflammatory cytokines (Figure 4.1A-D) and
infiltration of neutrophils and macrophages (Figure 4.1E-F) compared to the levels
observed in mice fed the LD.
Both LD and MD caused damage in resected and regenerated livers
Both of the resected and regenerated liver sections from mice fed either LD or MD
displayed higher NAFLD scores compared to the mice fed CD (Figure 4.2A). Liver
sections from the mice fed MD trended to have higher NAFLD scores compared to the
mice fed LD (Figure 4.2A).

Sera from mice fed LD or MD showed increased levels of

ALT (Figure 4.2B) and AST (Figure 4.2C) both on day-2 or day-7 compared to the mice
fed CD. This indicated higher levels of liver damage in the mice fed unsaturated or
saturated high fat diets. When compared between the mice fed LD and MD, sera from
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Figure 4.1. Unsaturated or saturated high fat diet led to the development of NASH in both resected and
regenerated livers. Both of the lard-based unsaturated and milk-based saturated high fat diet resulted in the
development of NASH as evidenced by increased expression of pro-inflammatory cytokines: (A) TNF-α, (B) IL1β, (C) TGF-β and (D) CCL-2; increased infiltration of (E) neutrophils and (F) macrophages. CD, LD, and MD
denote control diet, lard-based unsaturated and milk-based saturated high fat diet, respectively. *P<0.05,
**P<0.01, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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Figure 4.2. Unsaturated or saturated high fat diet resulted in liver damage in both resected and regenerated livers.
Unsaturated or saturated high fat diet resulted in (A) higher NAFLD scores and elevated level of serum (B) ALT and (C)
AST. (D) Western blot images demonstrated higher level of cleavage of poly ADP-ribose polymerase (PARP) in the livers
of mice fed unsaturated or saturated high fat diet ( shown regenerated day-2) (E) Densitometry analyses of immunoblots
exhibited increased level of cleavage of PARP in resected and regenerated livers of mice fed unsaturated or saturated high
fat diet. CD, LD, and MD denote control diet, lard-based unsaturated and milk-based saturated high fat diet, respectively.
*P<0.05, **P<0.01, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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the mice fed MD showed a higher trend of ALT and AST levels both on day-2 and day-7
compared to the mice fed LD.
Apoptosis resulting from the NASH-mediated hepatic tissue injury was determined
by comparing the level of cleaved poly ADP-ribose polymerase (PARP). Both resected
and regenerated tissues on day-2 or day-7 from the mice fed MD showed an increased
level of cleaved PARP compared to the mice fed CD (Figure 4.2D-E). Mice fed LD
showed an increased level of cleaved PARP in the tissues from the resected and
regenerated day-2 livers compared to the mice fed CD (Figure 4.2E). However, mice fed
MD displayed a higher trend of PARP cleavage compared to the mice fed LD in both
resected and regenerated livers on day-2 and day-7 (Figure 4.2E).
NASH-affected livers of mice fed MD or LD demonstrated impaired regeneration
following partial hepatectomy (PHx)
Percentage of BrdU-incorporated hepatocytes was determined in regenerated liver
sections on day-2 and day-7 in order to assess the effect of NASH on hepatic
regeneration following partial hepatectomy.

The percentage of BrdU-incorporated

hepatocytes was 2.2 and 5.2 fold lower in the regenerated liver sections of mice fed LD
or MD respectively compared to that of the regenerated liver sections of mice fed CD on
day-2 (Figure 4.3A). These data demonstrate the impaired hepatic regeneration in mice
fed fat-rich diet of either types compared to the mice fed control diet. Of note, percentage
of BrdU-incorporated hepatocytes was 2.3-fold lower in mice fed MD compared to the
mice fed LD. This observation was consistent with the higher trending indicators of NASH
(Figure 2.1), hepatic damage (Figure 4.2A-C) and apoptosis (Figure 4.3D-E) in the livers
of the mice fed MD when compared to the livers of mice fed LD. Because hepatic
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regeneration following PHx reached the level of saturation by day-7 [197], no significant
difference in BrdU incorporation was observed at day-7. However, the percentage of
BrdU-incorporated hepatocutes trended to be lower in the livers of mice fed LD or MD
compared to that incorporated into the livers of mice fed CD.
Regenerated liver output was measured as the ratio of regenerated liver-to-total
body weight (Figure 4.3B) or regenerated liver-to-resected liver weight (Figure 4.3C). In
either cases, ratios were lower in mice fed LD or MD compared to those of mice fed CD
on day-7.

Regenerated livers from the mice fed LD or MD showed a 1.3 and 1.2-fold

reductions to regenerated liver-to-body weight ratios, respectively compared to the mice
fed CD (Figure 4.3B).

Regenerated livers from the mice fed LD or MD were found to

have 1.7 and 1.6 fold reduction in their regenerated liver-to-resected liver weight ratio
respectively compared to the mice fed control diet (Figure 4.3C). These data again
corroborated the impaired regeneration of NASH-affected livers following PHx.
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Figure 4.3. Hepatic regeneration following partial hepatectomy was impaired in mice fed unsaturated or
saturated high fat diet. NASH induced through the consumption of high fat diets resulted in impaired regeneration of
partially resected livers as evidenced by (A) reduced rates of BrdU incorporation in hepatocytes, decreased (B)
regenerated liver/body ratio and (C) regenerated liver/resected liver ratio. CD, LD, and MD denote control diet, lardbased unsaturated and milk-based saturated high fat diet, respectively. *P<0.05, **P<0.01 (Man-Whitney test); data are
expressed as mean±SEM; n=6-8.
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Discussion
NASH is presently the third most common cause of end stage liver diseases necessitating
transplantation. If current trends continue, NASH is anticipated to surpass hepatitis C as
the dominant cause of liver failure and will likely increase the rate of hepatocellular
carcinoma (HCC) [23, 198]. Although liver transplantation has opened a new avenue for
the treatment of HCC, the benefit of this treatment is limited mainly by shortage of
available grafts and also long-term complications such as immunosuppression-related
infections, risk of tumor progression etc. Therefore, PHx is still considered as the most
viable treatment for HCC [199]. Because of the co-existence of NASH and HCC in a large
number of patients [200, 201], it is important to investigate how the presence of NASH
would affect hepatic regeneration in these patients following PHx. Absence of an
appropriate animal model that effectively mimics the genesis of human NASH represents
a barrier in being able to appreciate the consequences that NASH has on hepatic
regeneration following surgical resection.

However, amongst the currently available

genetic and dietary models, dietary fat induced NASH is clinically more relevant.
Previously, we have shown how employing a model requiring significant exposure to a
fat-rich diet was sufficient to induce and then mimic the complex behavior associated with
NASH that closely reflects what occurs in humans [163]. Our current data primarily
demonstrates that long-standing hepatic steatosis in mice fed high fat diet leads to NASH
and impairs hepatic regeneration following PHx. Comparison between the impacts of
unsaturated and saturated dietary fat on hepatic regeneration was an additional aspect
of this study. The data collected provided evidence for a trend towards higher levels of
expression of pro-inflammatory cytokines, increases in NAFLD score, collagen
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accumulation, serum ALT/AST levels and apoptosis in the livers of mice fed MD
compared to the mice fed LD indicating an exacerbating role of a diet high in saturated
fats in causing NASH. An exacerbation of impairment of hepatic regeneration following
PHx in the fatty livers of mice fed MD was consistent with a higher trend of hepatic
inflammation and hepatocyte damage compared to the mice fed LD. Such a higher trend
of hepatic inflammation can be attributed to aggravated oxidative stress, lipotoxicity, and
endoplasmic reticulum stress mediated by the saturated fat [164, 169]. In our study,
concentration of serum endotoxin was found to trend higher in mice fed MD compared to
the mice fed CD and LD (Chapter 5). Therefore, chronic endotoxemia might also be
plausible in offering an explanation for higher inflammation in mice fed MD. Several
NASH drugs are now under phase 3 clinical trials. Therefore, it would also be important
to test if the treatment of mice with a drug that reverses NASH could improve hepatic
regeneration post PHx. Treatment with such drug that suppresses NASH could make the
surgical resection a more viable treatment option for end stage liver diseases.
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Chapter 5
Gut Microbiota Plays a Critical Role in Nonalcoholic Steatohepatitis
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Summary
Apart from fat accumulation, additional pro-inflammatory insults to the steatotic
liver play an important role in the modulation of NASH. The role of gut microbiota has
been reported in metabolic syndrome. As NAFLD is the hepatic manifestation of
metabolic syndrome, it is important to investigate the role of gut microbiota in the
progression of disease from the benign hepatic steatosis to the stage with chronic
inflammation. Therefore, this part of our study investigated whether gut microbiota has
any influence on the development of NASH.

Three specific experiments were

accomplished: First, individual groups of specific pathogen free (SPF) mice and germ
free (GF) mice were fed a control diet (CD) or a milk based, saturated high fat diet (MD)
for 8, 16 or 32 weeks. The resulting decrease in the levels of NASH-indicative markers
in GF mice fed MD compared to the SPF mice fed MD indicated the role of gut microbiota
in mediating NASH. Second, it was tested if the diminishing of gut microbiota could
reduce the level of inflammation in the fatty livers of mice fed MD. In order to do that,
individual groups of SPF mice fed CD or MD were treated with broad spectrum antibiotics
through drinking water for 16 weeks. Treatment of mice fed MD with broad spectrum
antibiotics resulted in a reduced level of NASH-indicative markers in their livers indicating
the role of gut microbiota in modulating the dietary fat-mediated NASH.

Third,

conventionalization of GF mice fed MD by fecal transfer from SPF mice resulted in an
increased level of inflammation. These three experiments clearly showed the generalized
role of gut microbiota in causing NASH. In addition, 16S rRNA analysis resulted in
alteration of relative abundance of specific phyla in mice fed MD, indicating their plausible
role in mediating NASH.
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Introduction
Gut microbiota that dwell in the gastrointestinal tract consists of 100 trillion
bacterial cells that weigh 1-2 kg in mass and possess 100-fold more unique genes than
human genome [114, 202]. Gut microbiota play a crucial role in maintaining the normal
human physiology and nutrition [65, 203]. Changes in gut microbiota have been shown
to be associated with different metabolic and physiological disorders [86, 89, 122, 202,
204, 205]. The evidence supporting the contribution of gut-liver axis to the development
of NASH has accumulated over the last twenty years [206]. NASH was first encountered
as a complication of jejuno-ileal bypass surgery used for the treatment of morbid obesity
[207, 208]. Furthermore, NASH was also reported in case of jejunal diverticulosis and
intestinal bacterial overgrowth in human [209, 210]. Experimental evidence about the
role of gut microbiota in mediating NASH in animal models is also growing. Initial clues
came from the studies of Backhead and colleagues [85, 88]. They showed that germ free
(GF) mice fed high fat diet gained less weight compared to the specific pathogen free
(SPF) mice fed high fat diet. Conventionalization of GF mice through fecal transfer from
SPF mice resulted in an increase in body fat content [88]. Other studies have shown that
GF mice fed high fat diet are resistant to hepatic steatosis [211, 212]. One study reported
that transfer of gut microbiota from steatotic mice to GF mice can promote the
development of high fat diet-induced steatosis [211]. The pathogenic role of intestinal
bacteria in causing NASH was also supported by the observation that administration of
antibiotics can improve NASH in rat and human [213]. All of these studies suggested the
role of gut microbiota in the pathogenesis of NASH. Therefore, in this chapter,
comprehensive experiments were designed to demonstrate an obvious involvement of
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gut microbiota in mediating high fat diet-induced NASH using both GF and broad
spectrum antibiotics-treated mice. The role of gut microbiota in causing NASH was also
investigated through the restoration of gut microbiota in GF mice fed milk-based high fat
diet (MD). Any change to the population composition of gut microbes in mice fed high fat
diet may reveal a taxa-specific role of gut microbiota in mediating NASH. Therefore, 16S
rRNA analysis was performed to elucidate a plausible change in the composition of gut
microbial community in mice fed MD.
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Results
GF mice developed less steatosis in their livers compared to the SPF mice
After feeding with MD, GF mice showed less body weight and percent of body
weight increase compared to the SPF mice at week 8, 16 and 32 (Fig. 5.1A-B). GF mice
fed MD showed reduced liver weight and liver-to-body weight ratio compared to the SPF
mice fed MD at week 32 (Fig. 5.1C-D). H&E staining of the liver sections (Fig. 5.1E) and
clinical scores of steatosis (Fig. 5.1F) displayed a lower trend of fat accumulation in the
livers of GF mice fed MD compared to the SPF mice fed MD at week 16 and 32. These
data indicate the role of gut microbiota in mediating hepatic steatosis.
Steatotic livers in GF mice were resistant to NASH
To investigate the development of inflammation in steatotic livers, levels of different
NASH-indicative markers were analyzed. Expression levels of TNF-α, IL-1β, CCL-2 and
TGF-β (Fig. 5.2A-D) and infiltration of neutrophils and macrophages (Fig. 5.2E-F) in the
livers of GF mice fed MD failed to show any increase compared to the GF mice fed CD
at any time point. On the other hand, SPF mice fed MD showed significant increases of
expression of TNF-α, IL-1β, CCL-2 and TGF-β (Fig. 5.2A-D) and infiltration of neutrophils
and macrophages (Fig. 5.2E-F) compared to the GF mice fed MD at week 16 and 32.
Although there was an increase of NAFLD score in GF mice fed MD compared to the GF
mice fed CD at week 16 and 32 (Fig. 5.2G), it was significantly lower (approximately 1.3
to 2-fold) than the SPF mice fed MD. These data demonstrate that the steatotic livers in
GF mice fed MD are protected from NASH, thus indicating the role of gut microbiota in
the progression of NASH from the normal steatosis to an inflammatory stage.

63

A

Body weight

B

Body weight change

C

Liver weight

D

Liver / body

64

E

SPF

GF

CD

MD

F

Steatosis score

Figure 5.1. Germ free mice fed high fat diet developed less hepatic steatosis compared to the specific pathogen
free mice. Feeding with high fat diet resulted in less (A) body weight, (B) body weight change, (C) livers weight and (D)
liver-to-body weight ratio in germ free mice compared to the specific pathogen free mice. Less steatosis was observed
in the livers of germ free mice fed high fat diet compared to the specific pathogen free mice fed high fat diet as shown by
the (E) representative images of H&E stained liver sections (at 16 weeks) and (F) steatosis score. GF, SPF, CD and MD
denote germ free mice, specific pathogen free mice, control diet and milk-based high fat diet, respectively. *P<0.05,
**P<0.01, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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Figure 5.2. Germ free mice fed high fat diet showed lower levels of NASH-indicative markers in their livers
compared to the specific pathogen free mice fed high fat diet. Germ mice fed high fat diet showed lower levels
of (A-D) expression of TNF-α. IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, and (G)
NAFLD score in their livers compared to the specific pathogen free mice fed high fat diet. GF, SPF, CD and MD
denote germ free mice, specific pathogen free mice, control diet and milk-based high fat diet, respectively. *P<0.05,
**P<0.01, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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GF mice fed MD had decreased level of collagen accumulation in their livers
compared to the SPF mice fed MD
Collagen accumulation, a sign of hepatic fibrosis, is very common in chronic inflammation
in fatty liver [140]. Therefore, the level of collagen accumulation was determined as a
strong indicator of NASH. Reduced level of collagen accumulation was observed in
picrosirius red-stained liver sections of GF mice fed MD compared to the SPF mice fed
MD at week 16 and 32 (data shown at 16 week, Fig. 5.3A). Reduced level of collagen
accumulation was reflected in the decreased expression of Col-1 and α-SMA, two
important pro-fibrotic proteins [214, 215], in the livers of GF mice fed MD compared to the
SPF mice fed MD (Fig. 5.3B-C).
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Figure 5.3. Germ free mice fed high fat diet showed decreased level of collagen accumulation in their livers
compared to the specific pathogen free mice. Feeding high fat diet resulted in decreased level of collagen
accumulation in the livers of germ free mice compared to the specific pathogen free mice as shown by the (A)
representative images of picrosirius red stained liver sections (at 16 weeks) and expression of (B) Col-1a and (C) αSMA. GF, SPF, CD and MD denote germ free mice, specific pathogen free mice, control diet and milk-based high fat
diet, respectively. *P<0.05, **P<0.01, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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Broad spectrum antibiotics-treated mice fed MD showed similar levels of steatosis,
but had a decreased level of NASH compared to the control mice fed MD
The treatment of mice fed MD with broad spectrum antibiotics failed to make any
difference in the level of steatosis in their livers compared to the control mice fed MD (Fig.
5.4A). Similar clinical scores of steatosis were observed in the livers of broad spectrum
antibiotic-treated mice and control mice (Fig. 5.4B). Although the treatment of mice fed
MD with broad spectrum antibiotic did not result in any difference in the level of hepatic
steatosis, it resulted in decreased levels of NASH-indicative markers in the livers of
antibiotic-treated mice fed MD compared to the control mice fed MD (Fig. 5.5). Broad
spectrum antibiotic-treated mice fed MD showed decreased expression of TNF-α, IL-1β,
CCL-2 and TGF-β, reduced infiltration of neutrophils and macrophages, and lower trends
of serum activities of ALT and AST and NAFLD scores when compared to the control
mice fed MD (Fig. 5.5A-I). Decreased level of NASH in the livers of broad spectrum
antibiotic-treated mice fed MD resulted in improved liver health as demonstrated by
significantly higher liver-to-body weight ratio compared to the control mice fed MD (Fig.
5.5J). Picrosirius red stained liver sections demonstrated that broad spectrum antibiotictreated mice fed MD had decreased accumulation of collagen in their livers when
compared to the control mice fed MD (Fig. 5.6A). Broad spectrum antibiotic-treated mice
fed MD showed a lower trend of expression of pro-fibrotic Col-1 and α-SMA in their livers,
(Fig. 5.6A) which corroborates the reduced accumulation of collagen. Collectively,
decreased levels of NASH-indicative and pro-fibrotic markers in the livers of broad
spectrum antibiotic-treated mice fed MD, when compared to the control mice fed MD,
suggesting the role of gut microbiota in mediating chronic inflammation in steatotic liver.
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Figure 5.4. Broad spectrum antibiotic-treated mice fed high fat diet developed similar level of hepatic
steatosis compared to the control mice. Feeding with high fat diet resulted in similar steatosis in the livers of broad
spectrum antibiotic-treated mice compared to the control mice as shown by the (A) representative images of H&E
stained liver sections and (B) steatosis score. CD and MD denote control diet and milk-based high fat diet,
respectively. Data are expressed as mean±SEM; n=6-8.
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Figure 5.5. Broad spectrum antibiotic-treated mice fed high fat diet showed decreased levels
of NASH-indicative markers compared to the control mice fed high fat diet. Broad spectrum
antibiotic-treated mice fed high fat diet showed lower levels of (A-D) expression of TNF-α, IL-1β, CCL2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum activities of ALT and AST,
and (I) NAFLD scores in their livers compared to the control mice fed high fat diet. (J) Decreased level
of NASH resulted in better liver health as demonstrated by higher liver-to-body weight ratio in broad
spectrum antibiotic-treated mice fed MD compared to the control mice fed MD. CD and MD denote
control diet and milk-based high fat diet, respectively. *P<0.05, **P<0.01, ***P<0.001 (Man-Whitney
test); data are expressed as mean±SEM; n=6-8.
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Figure 5.6. Broad spectrum antibiotic-treated mice fed high fat diet showed decreased level of collagen
accumulation in their livers compared to the control mice fed high fat diet. Broad spectrum antibiotictreated mice fed high fat diet displayed a lower trend of collagen accumulation in their livers compared to the
control mice fed high fat diet as shown by the (A) representative images of picrosirius red stained liver sections
and expression of (B-C) Col-1a and α-SMA. CD and MD denote control diet and milk-based high fat diet,
respectively. (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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Conventionalization of GF mice fed MD resulted in increased level of NASH
To gain further evidence for the role of gut microbiota in mediating NASH, GF mice
fed MD were conventionalized through the re-constitution of gut microbiota by fecal
transplantation from SPF mice fed MD. Re-constitution of gut microbiota in GF mice fed
MD did not result in any difference in the level of steatosis in their livers as compared to
the GF mice fed MD. H&E staining of liver sections and their clinical scores for steatosis
displayed a level of steatosis in the livers of gut microbiota re-constituted mice fed MD,
that was similar to the steatosis observed in the livers of GF and control SPF mice fed
MD (Fig. 5.7A-B). Although the level of steatosis remained unchanged, the levels of
different NASH-indicative markers significantly increased in the livers of gut microbiota
re-constituted mice when compared to the GF mice (Fig. 5.8A-G). Expression of TNF-α,
IL-1β, CCL-2 and TGF-β (Fig. 5.8A-D) and infiltration of neutrophils and macrophages
(Fig. 5.8E-F) were increased in the livers of gut microbiota reconstituted mice fed MD as
compared to the GF mice fed MD. Increased levels of these inflammatory markers
resulted in a higher trend of NAFLD score in gut microbiota re-constituted mice as
compared to the GF mice (Fig. 5.8G). Re-constitution of gut microbiota in GF free mice
fed MD also resulted in an increased accumulation of collagen as demonstrated by
picrosirius red staining of liver sections (Fig. 5.9A).

This increase in collagen

accumulation was also reflected in increased expression of Col-1 and α-SMA in the livers
of gut microbiota re-constituted mice fed MD compared to the GF mice fed MD (Fig. 5.9BC). These data clearly demonstrated the role of gut microbiota in causing NASH.
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Figure 5.7. Reconstitution of gut microbiota in germ free mice fed high fat diet did not make any
difference in the hepatic steatosis. Feeding with high fat diet resulted in similar steatosis in the livers of
conventionalized (gut microbiota re-constituted) mice compared to the germ free mice as shown by the (A)
representative images of H&E stained liver sections and (B) steatosis score. GF, GMR, SPF and MD denote
germ free mice, gut microbiota re-constituted mice, specific pathogen free mice and milk-based high fat diet,
respectively. Data are expressed as mean±SEM; n=6-8.
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Figure 5.8. Reconstitution of gut microbiota in germ free mice fed high fat diet showed elevated levels of
NASH-indicative markers in their steatotic livers. Reconstitution of gut microbiota in germ free mice fed high fat
diet resulted in increased levels of (A-D) expression of TNF-α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils
and macrophages, and (G) NAFLD scores in their livers compared to the germ free mice. GF, GMR, SPF and MD
denote germ free mice, gut microbiota re-constituted mice, specific pathogen free mice and milk-based high fat diet,
respectively. *P<0.05, **P<0.01, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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Figure 5.9. Reconstitution of gut microbiota in germ free mice fed high fat diet resulted in increased
collagen accumulation in their steatotic livers. Reconstitution of gut microbiota in germ free mice fed high fat
diet displayed an increase in collagen accumulation in their livers compared to the germ free mice fed high fat diet
as shown by the (A) representative images of picrosirius red stained liver sections and expression of (B-C) Col-1a
and α-SMA. GF, GMR, SPF and MD denote germ free mice, gut microbiota re-constituted mice, specific pathogen
free mice and milk-based high fat diet, respectively. *P<0.05 (Man-Whitney test); data are expressed as mean±SEM;
n=6-8.
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Composition of gut microbial community was altered in mice fed MD
To determine whether a high fat diet could bring about a change in the structure of
gut microbial community, which might better explain the observed role of gut microbiota
in mediating NASH in the livers of mice fed MD, the composition of cecal microbiota was
determined at phylum level using 16s rRNA analysis. Indeed, the composition of gut
microbial community was changed in mice fed MD. Stacked bar diagram of gut microbial
community revealed a shift in phylum level in mice fed MD as compared to the mice fed
CD (Fig. 5.10A). Structure of gut microbial community in mice fed MD became similar to
mice fed CD when the diet was switched from MD to CD. Relative abundances of
Bacteroidetes, Actinobacteria, and Tenericutes were significantly decreased in mice fed
MD as compared to the mice fed CD.

On the other hand, relative abundances of

Proteobacteria, Verrucobacteria, and Firmicutes were significantly increased in mice fed
MD as compared to the mice fed CD (Fig. 5.10B-G). When the diet was switched from
MD to CD, relative abundances of these six gut microbial phyla became similar to the
mice fed CD. Within the phylum Firmicutes, relative abundance of genus Clostridium
trended to be higher in mice fed MD which became similar to the mice fed CD upon the
change of diet from MD to CD (Fig. 5.10H). Principal component analysis was performed
based on the composition of gut microbiota in order to assess whether the mice fed MD
were clustered differently than the mice fed CD. Likewise, as we anticipated mice fed MD
clustered differently versus the mice fed CD (Fig. 5.11A-B). However, mice fed MD
clustered similarly to the mice fed CD when the diet was changed from MD to CD,
demonstrating that the composition of gut microbial community differs in mice fed MD
versus mice fed CD.
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Figure 5.10. Composition of gut microbiota changed in mice fed high fat diet. Feeding of mice with high fat diet for
16 weeks resulted in alteration of composition of gut microbial community which became similar to that of mice fed control
diet upon the switch of diet from control diet to high fat diet as represented by (A) stacked bar diagram at phylum level and
changes in relative abundances of (B) Bacteroidetes, (C) Proteobacteria, (D) Verrucobacteria, (E) Firmicutes, (F)
Actinobacteria, (G) Tenericutes, and (H) Clostridium. CD, MD and MD>CD denote control diet, milk-based high fat diet and
switched diet, respectively. *P<0.05 (Man-Whitney test); data are expressed as mean±SEM; n=4-8.

81

Figure 5.11. Principal component analysis resulted in different clustering of mice fed high fat diet.
Principal component analysis based on the relative abundances of gut microbes at phylum level resulted in
different clustering of mice fed high fat diet than mice fed control diet. When the diet was switched from high
fat diet to control diet, mice fed high fat diet clustered similar to the mice fed control diet. CD, MD and MD>CD
denote control diet, milk-based high fat diet and switched diet, respectively. Dark-filled dots, pink-filled dots
and open dots indicate the mice fed CD, MD and MD>CD respectively.
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Discussion
In order to demonstrate the association of gut microbiota in transferring a steatotic
liver to one with NASH, three specific experiments were conducted in this study. First
experiment was performed using GF mice which showed that GF mice fed MD are
protected from NASH. Second experiment was performed by the treatment of SPF mice
fed MD with broad spectrum antibiotics.

Diminishing of gut microbiota through the

treatment with broad spectrum antibiotics resulted in decreased levels of NASH-indicative
markers in SPF mice fed MD. Data from the experiment with broad spectrum antibiotics
treatment was in line with the findings of GF mice experiment. Finally, in
conventionalization experiment, gut microbiota was reconstituted in GF mice fed MD
through fecal transfer from SPF mice fed MD, which resulted in increased levels of NASHindicative markers.
Although the level of chronic inflammation in steatotic liver was decreased in both
GF and broad spectrum antibiotics-treated mice as compared to the control mice, GF
mice demonstrated better protection than broad spectrum antibiotics-treated mice.
Whereas the GF mice fed MD were completely protected from elevated expression of
pro-inflammatory cytokines and increased infiltration of innate immune cells, broad
spectrum antibiotics-treated mice fed MD showed only a partial decrease in these NASHindicative markers, perhaps because gut microbes are not completely eliminated through
broad spectrum antibiotic treatment [216], while GF mice are free from all microbes.
Therefore, it is possible that pro-inflammatory components coming from the remaining gut
microbes of broad spectrum antibiotics-treated mice still have some causative effect on
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the mediation of NASH. At the same time, plausible direct therapeutic effect of antibiotics
on the pathogenesis of NASH cannot be ruled out.
Although the re-constitution of gut microbiota in GF mice fed MD resulted in an
increase in the level of immune infiltration in their livers, it did not reach the level of
immune infiltration in the livers of control SPF mice fed MD. Perhaps, that occurred due
to the fact that gut microbiota-derived metabolites (e.g. short chain fatty acids) play an
important role in the differentiation of embryonic immune progenitor cells, particularly the
macrophage progenitor cells [217]. A defective prenatal differentiation of these immune
progenitor cells may occur in the liver of GF mice due to the deficiency of gut microbiotaderived metabolites. Immune cells derived from this progenitor cells are called sessile
cells. It is possible that a portion of the sessile immune cells is deficient in the liver of GF
mice due to the lack of gut microbiota-derived factors. Postnatal re-constitution of gut
microbiota in GF mice through fecal transplantation could only facilitate the differentiation
of bone marrow-derived innate cells in the liver, but not compensate the missing sessile
cells [218]. Therefore, the level of immune cell count in the liver of conventionalized GF
mice never reached the level in SPF mice.
Data from 16s rRNA analysis, as displayed by stacked bar diagram and principal
component analysis, demonstrated a change in the composition of gut microbiota in mice
fed MD as compared to the mice fed CD.

Although the relative abundance of

Bacteroidetes, the major Gram negative phylum in the gut microbiota of mice, decreased,
the relative abundance of two different Gram negative phyla, Proteobacteria and
Verrucobacteria, significantly increased in the mice fed MD [219]. The important change
in the relative abundance of Gram negative bacteria is mainly due to their contribution in
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producing endotoxin.

It is still unclear how much of a role Proteobacteria or

Verrucobacteria plays in maintaining the level of circulating endotoxin. Apart from the
alteration of gut microbial composition in the phylum level, we also observed a change in
genus Clostridium in mice fed MD. Clostridium produces ethanol which, importantly,
contributes to oxidative stress in the liver leading to NASH [220]. It requires further
investigation to identify specific microbes potentially associated with the production of
pro-inflammatory molecules or metabolites associated with NASH. In that case,
application of microbe-specific antibiotics other than broad spectrum antibiotics may
create a new therapeutic option for NASH.
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Chapter 6
Role of Gut Microbiota in Causing NASH is Dependent on LPS-TLR-4Kupffer Cell Axis
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Summary
Increased level of LPS has been reported both in obese patients and experimental
models of obesity. It has also been reported that chronic administration of LPS in mice
results in increased adipose tissue and body weight in a TLR-4 pathway-dependent
manner. In the previous chapter, we demonstrated the obvious role of gut microbiota in
causing NASH. LPS is known as a major gut-derived pro-inflammatory component in the
liver. Therefore, it demands a comprehensive study to investigate the potential role of
LPS-TLR-4 pathway in the modulation of NASH by gut microbiota. Treatment of mice fed
MD with broad spectrum antibiotics resulted in decreased concentration of serum LPS
and indicators of NASH. Chronic injection of low dose LPS restored the higher level of
serum LPS in mice fed MD. The level of NASH was also increased upon injection of LPS
corroborating the role of LPS in causing NASH. Simultaneous injection of TAK-242, a
TLR-4 inhibitor, protected the mice fed MD from NASH demonstrating the role of LPSTLR-4 pathway in causing the disease. It was also observed that TLR-4 KO mice fed MD
had deceased level of NASH. Chronic injection of LPS in TLR-4 KO mice fed MD failed
to increase the level of NASH. This observation further confirmed the involvement of
LPS-TLR-4 pathway in causing NASH. Because kupffer cells are the principal member
of TLR-4-expressing community in the liver, we also attempted to investigate the role of
kupffer cells in mediating NASH. It was found that reconstitution of TLR-4 KO kupffer
cells in the livers of wild-type mice fed MD by bone marrow transplantation resulted in a
decreased level of NASH. Conversely, reconstitution of wild-type kupffer cells in the livers
of TLR-4 KO mice fed MD resulted in an increased level of NASH. This experiment clearly
indicated the role of kupffer cells in mediating NASH in a TLR-4 dependent manner.
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Introduction
Once the involvement of gut microbiota in causing NASH is demonstrated, the next
question to resolve is the mechanism how gut microbiota contributes to NASH
modulation. One potential mechanism might be the engagement of TLRs and their gut
microbiota-derived ligands known as microbe-associated molecular patterns. LPS is a
major microbe-associated molecular pattern drained into the portal circulation from
intestine. The concentration of LPS has been shown to be increased in obese patients
as well as animal models of obesity [122, 123, 221, 222]. Role of LPS-TLR-4 pathway in
metabolic syndrome was first studied by Cani et al. They showed that chronic
endotoxemia created through the infusion of LPS using a subcutaneously implanted
osmotic mini-pump had resulted in an increased body weight and adipose tissue in mice
[122]. In the same report, they also showed that interruption of TLR-4 pathway through
the knockout of CD14 prevents the LPS-infused mice from gaining increased body weight
and adipose tissue. These data demonstrated the role of LPS-TLR-4 pathway in obesity.
In a follow-up report, Cani et al. showed that treatment of mice fed high fat diet with broad
spectrum antibiotics had resulted in a reduced concentration of serum LPS and
decreased body weight and adipose tissue, when compared to the control mice fed a high
fat diet. This result demonstrated that gut microbiota plays a role in controlling obesity
through metabolic endotoxemia. Due to the close association of obesity and NAFLD, a
similar role for the LPS-TLR-4 pathway is postulated in the pathogenesis of NASH.
Therefore, the current study was designed to investigate the role of a gut-derived low
grade chronic endotoxemia in causing NASH in mice fed high fat diet in a TLR-4 pathwaydependent manner.
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Results
Diminishing of gut microbiota resulted in reduced concentration of serum
endotoxin which was restored upon LPS injection
Diminishing of gut microbiota through the treatment of mice fed CD or MD with
broad spectrum antibiotics resulted in reduced concentration of endotoxin in portal serum
and feces (Fig. 6.1A-B). This indicates that the concentration of serum endotoxin is
dependent on the normal abundance of gut microbiota. Injection i.p. of low dose LPS for
four weeks led to the increase of concentration of endotoxin in portal serum (Fig. 6.1A).
LPS injection resulted in increased level of NASH in broad spectrum antibioticstreated mice that were fed MD
As discussed in the last chapter, treatment of mice fed MD with broad spectrum
antibiotics resulted in decreased level of NASH. This improvement of disease might be
due to the reduced concentration of gut-derived endotoxin in the circulation of broad
spectrum antibiotics-treated mice. This assumption led us to test if the restoration of an
increased level of serum endotoxin through the injection i.p. of a subclinical dose of
exogenous LPS in broad spectrum antibiotics-treated mice could increase the severity of
NASH. LPS injection in broad spectrum antibiotics-treated mice fed MD, however, did
not make any difference in fat accumulation and steatosis score (Fig. 6.2A and Fig. 6.2B),
but that LPS injection did result in increased levels of expression of TNF-α, IL-1β, CCL-1
and TGF-β, infiltration of neutrophils and macrophages, serum activities of ALT and AST
and clinical scores of NAFLD as compared to the non-LPS injected/antibiotics-treated
mice fed MD (Fig. 6.3A-I). Elevated levels of the aforementioned indicators of NASH
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Figure 6.1. Diminishing of gut microbiota resulted in reduced concentration of endotoxin in portal serum
and feces. Treatment of mice fed CD or MD with broad spectrum antibiotics resulted in reduced concentration
of endotoxin in (A) portal serum and (B) feces. (A) Intraperitoneal injection of low dose LPS restored the serum
endotoxin level in mice fed MD. CD and MD denote control diet and milk-based high fat diet, respectively.
***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.

90

were reflected in exacerbated liver health as shown by the reduced liver-to-body weight
ratios of LPS-injected/antibiotics-treated mice fed MD, when compared to the only
antibiotics-treated mice fed MD (Fig. 6.3J).
LPS injection also resulted in increased collagen accumulation in the fatty livers of
broad spectrum antibiotics-treated mice fed MD compared to the only antibiotics-treated
mice fed MD, as demonstrated by elevated levels of picrosirius red staining of collagen
and expression of col-1 and α-SMA (Fig. 6.4A-C). These data demonstrated the role of
the low concentration of gut-derived endotoxin in mediating NASH in the fatty liver.
Administration of TLR-4 inhibitor (TAK-242) blunted the effect of injection of low
dose LPS resulting in decreased level of NASH
Administration of TAK-242 in antibiotics-treated/LPS-injected mice fed MD did not
make any significant decrease in fat accumulation or steatosis score (Fig. 6.2A and Fig.
6.2B), but resulted in reduced levels of expression of TNF-α, IL-1β, CCL-1 and TGF-β,
infiltration of neutrophils and macrophages, serum activities of ALT and AST and clinical
scores of NAFLD compared to the only antibiotics-treated/LPS-injected mice fed MD (Fig.
6.3A-I). Reduced level of NASH was consistent with the improved liver health as shown
by the increased liver-to-body weight ratios in antibiotics-treated/LPS-injected/TAK-242administered mice fed MD, as compared to the only antibiotics-treated/LPS-injected mice
fed MD (Fig. 6.3J).
Administration of TAK-242 also resulted in reduced collagen accumulation in the
fatty livers of broad spectrum antibiotics-treated/LPS-injected mice fed MD compared to

91

A

B

Steatosis score

Figure 6.2. Injection of LPS or TLR-4 inhibitor in broad spectrum antibiotics-treated mice fed high fat
diet did not make alter hepatic steatosis. Intraperitoneal injection of low dose LPS or TLR-4 inhibitor (TAK242) in mice fed CD or MD did not alter hepatic steatosis as shown by (A) representative images of H&E
stained liver sections and (B) steatosis score. CD and MD denote control diet and milk-based high fat diet,
respectively. Data are expressed as mean±SEM; n=6-8.
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Figure 6.3. Injection of low dose LPS in broad spectrum antibiotics-treated mice fed high fat diet resulted
in increased level of NASH which was reversed upon administration of TLR-4 inhibitor. Injection of low
dose LPS in broad spectrum antibiotics-treated mice fed MD resulted in increased levels of (A-D) expression of
TNF-α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum activities of ALT
and AST, and (I) NAFLD scores in their livers which was reversed upon administration of TLR-4 inhibitor (TAK242). (J) Increased level of NASH in LPS-injected/antibiotics-treated mice fed MD resulted in exacerbated liver
health as demonstrated by reduced liver-to-body weight ratio which was reversed upon administration of TAK242. CD and MD denote control diet and milk-based high fat diet, respectively. *P<0.05, **P<0.01, ***P<0.001
(Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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Figure 6.4. Injection of low dose LPS in broad spectrum antibiotics-treated mice fed high fat diet resulted in
increased accumulation of collagen which was reversed upon administration of TLR-4 inhibitor. Injection of
low dose LPS in broad spectrum antibiotics-treated mice fed MD displayed an increased level of collagen accumulation
in their livers which was reversed upon administration of TLR-4 inhibitor (TAK-242) as shown by the (A) representative
images of picrosirius red stained liver sections and expression of (B-C) Col-1a and α-SMA. CD and MD denote control
diet and milk-based high fat diet, respectively. *P<0.05, ***P<0.001 (Man-Whitney test); data are expressed as
mean±SEM; n=6-8.
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the antibiotics-treated/LPS-injected mice fed MD, as demonstrated by reduced levels of
picrosirius red staining of collagen and expression of col-1 and α-SMA (Fig. 6.4A-C).
These results demonstrate that circulating LPS induces inflammation in the fatty liver
through the interaction with TLR-4 indicating an important role of LPS-TLR-4 axis in
causing NASH.
TLR-4 has an obvious role in the modulation of NASH in mice fed MD
Livers from TLR-4 KO mice fed MD did not show any difference in fat accumulation
or steatosis score as compared to the wild-type mice fed MD (Fig. 6.7A-B). Likewise,
injection of low dose LPS in TLR-4 KO mice fed MD did not cause any difference in fat
accumulation or steatosis score as compared to the wild-type or TLR-4 KO mice fed MD
(Fig. 6.7A-B). These data indicate that TLR-4 does not have a clear role in fat deposition
in the liver.
Although TLR-4 did not show any role in fat accumulation in the livers of mice fed
MD, yet it showed important role in the transitioning of fatty livers to chronic inflammatory
stage. TLR-4 KO mice fed MD exhibited reduced levels of expression of TNF-α, IL-1β,
CCL-1 and TGF-β, infiltration of neutrophils and macrophages, serum activities of ALT
and AST and clinical scores of NAFLD, as compared to the wild-type mice fed MD (Fig.
6.8A-I). Injection of low dose LPS in TLR-4 KO mice did not result in any increase in the
levels of NASH-indicative markers as compared to the Only TLR-4 KO mice fed MD. The
reduced level of NASH was consistent with the improved liver health, as shown by the
increased liver-to-body weight ratios in TLR-4 KO mice fed MD, when compared to the
wild-type mice fed MD (Fig. 6.8J). Injection of low dose LPS in TLR-4 KO mice fed MD
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Figure 6.7. TLR-4 KO mice fed high fat diet displayed similar level of hepatic steatosis as compared to the
wild-type mice fed high fat diet. TLR-4 KO and wild-type mice fed MD did not display any difference in hepatic
steatosis as shown by the (A) representative images of H&E stained liver sections and (B) steatosis score.
Intraperitoneal injection of low dose LPS in TLR-4 KO mice fed MD did not make any difference in hepatic steatosis
as compared to the wild-type or TLR-4 KO mice fed MD. CD and MD denote control diet and milk-based high fat diet,
respectively. Data are expressed as mean±SEM; n=6-8.
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Figure 6.8. TLR-4 KO mice fed high fat diet exhibited decreased level of NASH which remained unchanged
upon injection of low dose LPS. TLR-4 KO mice fed MD showed decreased levels of (A-D) expression of TNFα, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum activities of ALT and
AST, and (I) NAFLD scores in their livers as compared to the wild-type mice fed MD which remained unchanged
upon low dose LPS injection. (J) Decreased level of NASH in TLR-4 KO mice fed MD resulted in improved liver
health as demonstrated by increased liver-to-body weight ratio which remained unchanged upon low dose LPS
injection. CD and MD denote control diet and milk-based high fat diet, respectively. *P<0.05, **P<0.01, ***P<0.001
(Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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did not result in any significant difference in the levels of NASH-indicative markers as
compared to the TLR-4 KO mice fed MD with no LPS injection.
TLR-4 KO mice fed MD exhibited reduced collagen accumulation in their fatty livers
as compared to the wild-type mice fed MD as demonstrated by reduced levels of
picrosirius red staining of collagen and expression of col-1 and α-SMA (Fig. 6.9A-C).
Injection of low dose LPS in TLR-4 KO mice fed MD did not make any increase in collagen
accumulation in their livers as compared to the TLR-4 KO mice fed MD with no LPS
injection. These data demonstrate the role of TLR-4 in mediating NASH in mice fed MD.
TLR-4-expressing kupffer cells play a crucial role in mediating NASH in mice fed
MD
Once the role of LPS-TLR-4 axis in causing NASH is demonstrated, the next
question naturally rises is the role of kupffer cells, as they are the major TLR-4-expressing
cells in the liver.

To address this question, wild-type mice fed CD or MD were

reconstituted with TLR-4 KO kupffer cells, and TLR-4 KO mice fed CD or MD were
reconstituted with wild-type kupffer cells through bone marrow transplantation. It was
observed that the reconstitution of TLR-4 KO kupffer cells in the livers of wild-type mice
fed MD by bone marrow transplantation resulted in a decreasing trend of fat accumulation
and steatosis score, as compared to the TLR-4+ kupffer cells-containing wild-type mice
fed MD. On the other hand, reconstitution of wild-type kupffer cells in the livers of TLR-4
KO mice fed MD resulted in an increasing trend of fat accumulation and steatosis score,
as compared to the TLR-4 KO kupffer cells-containing TLR-4 KO mice fed MD (Fig.
6.10A-B). These data indicate that TLR-4-expressing kupffer cells are involved in the
process of fat accumulation in the livers of mice fed MD.
100

A

B

Col-1

C

α-SMA

Figure 6.9. TLR-4 KO mice fed high fat diet displayed decreased level of collagen accumulation in their livers
which remained unchanged upon injection of low dose LPS. TLR-4 KO mice fed MD showed decreased level of
collagen accumulation in their livers as compared to the wild-type mice fed MD which remained unchanged upon
injection of low dose LPS as shown by the (A) representative images of picrosirius red stained liver sections and
expression of (B-C) Col-1a and α-SMA. CD and MD denote control diet and milk-based high fat diet, respectively.
*P<0.05, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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Figure 6.10. TLR-4-expressing kupffer cells are involved in the accumulation of fat in mice fed high fat diet.
Reconstitution of TLR-4 KO kupffer cells in the livers of wild-type mice fed MD resulted in a decreasing trend of hepatic
steatosis as compared to the TLR-4+ kupffer cells-containing wild-type mice fed MD; also, reconstitution of wild-type
kupffer cells in the livers of TLR-4 KO mice fed MD resulted in an increasing trend of hepatic steatosis as compared to
the TLR-4 KO kupffer cells-containing TLR-4 KO mice fed MD as shown by the (A) representative images of H&E
stained liver sections and (B) steatosis score. CD and MD denote control diet and milk-based high fat diet, respectively.
Data are expressed as mean±SEM; n=6-8.
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Regarding the inflammation in the fatty liver, reconstitution of TLR-4 KO kupffer
cells in the livers of wild-type mice fed MD by bone marrow transplantation resulted in
reduced levels of expression of TNF-α, IL-1β, CCL-1 and TGF-β, infiltration of neutrophils
and macrophages, serum activities of ALT and AST and clinical scores of NAFLD, when
compared to the TLR-4+ kupffer cells-containing wild-type mice fed MD. In the same time,
reconstitution of wild-type kupffer cells in the livers of TLR-4 KO mice fed MD resulted in
increased levels of expression of TNF-α, IL-1β, CCL-1 and TGF-β, infiltration of
neutrophils and macrophages, serum activities of ALT and AST and clinical scores of
NAFLD, when compared to the TLR-4 KO kupffer cells-containing TLR-4 KO mice fed
MD. (Fig. 6.11A-I). Decreased level of NASH in the livers of wild-type mice fed MD
reconstituted with TLR4-KO kupffer cells was reflected in improved liver health, as
demonstrated by the increased liver-to-body weight ratios. Increased level of NASH in
the livers of TLR-4 KO mice fed MD reconstituted with wild-type kupffer cells was reflected
in exacerbated liver health, as shown by the decreased liver-to-body weight ratios (Fig.
6.11J).
Wild-type mice fed MD reconstituted with TLR4-KO kupffer cells exhibited reduced
collagen accumulation in their livers, when compared to the wild-type mice fed MD
containing TLR-4+ kupffer cells, as demonstrated by reduced levels of picrosirius red
staining of collagen and expression of col-1 and α-SMA (Fig. 6.12A-C). On the other
hand, reconstitution of wild-type kupffer cells in the livers of TLR-4 KO mice fed MD
resulted in increased collagen accumulation in their livers, when compared to the TLR-4
KO mice fed MD containing TLR-4 KO kupffer cells, as shown by increased levels of
picrosirius red staining of collagen and expression of col-1 and α-SMA (Fig. 6.12A-C).

103

A

TNF-α

B

IL-1β

C

CCL-2

D

TGF-β

E

Neutrophils

F

104

Macrophages

G

ALT

H

I

NAFLD

J

AST

Liver/body

Figure 6.11. TLR-4-expressing kupffer cells play crucial role in mediating NASH in mice fed high fat diet.
Reconstitution of TLR-4 KO kupffer cells in the livers of wild-type mice fed MD resulted in decreased levels of (AD) expression of TNF-α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum
activities of ALT and AST, and (I) NAFLD scores as compared to the TLR-4+ kupffer cells-containing wild-type
mice fed MD. (J) Decreased level of NASH in wild-type mice fed MD reconstituted with TLR-4 KO kupffer cells
resulted in improved liver health as demonstrated by increased liver-to-body weight ratios. On the other hand,
Reconstitution of wild-type kupffer cells in the livers of TLR-4 KO mice fed MD resulted in increased levels of (AD) expression of TNF-α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum
activities of ALT and AST, and (I) NAFLD scores as compared to the TLR-4 KO kupffer cells-containing TLR-4
KO mice fed MD. (J) Increased level of NASH in TLR-4 KO mice fed MD reconstituted with wild-type kupffer cells
resulted in exacerbated liver health as demonstrated by decreased liver-to-body weight ratios. CD and MD denote
control diet and milk-based high fat diet, respectively. *P<0.05, **P<0.01, ***P<0.001 (Man-Whitney test); data
are expressed as mean±SEM; n=6-8.
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Figure 6.12. TLR-4-expressing kupffer cells play an important role in collagen accumulation in the livers of
mice fed high fat diet. Reconstitution of TLR-4 KO kupffer cells in the livers of wild-type mice fed MD resulted in
decreased level of collagen accumulation in their livers as compared to TLR-4+ kupffer cells-containing wild-type mice
fed MD as shown by the (A) representative images of picrosirius red stained liver sections and expression of (B-C)
Col-1a and α-SMA. On the other hand, reconstitution of wild-type kupffer cells in the livers of TLR-4 KO mice fed MD
resulted in increased level of collagen accumulation in their livers as compared to TLR-4 KO kupffer cells-containing
TLR-4 KO mice fed MD as shown by the (A) representative images of picrosirius red stained liver sections and
expression of (B-C) Col-1a and α-SMA. CD and MD denote control diet and milk-based high fat diet, respectively.
*P<0.05, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8.
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Reconstituted kupffer cells were derived from the transplanted bone marrow
It is an important question whether the kupffer cells can actually be reconstituted
from the transplanted bone marrow. To address this question, bone marrow cells isolated
from CD45.1 mice were transplanted into lethally-irradiated and chlodronate-treated (to
deplete existing kupffer cells) congenic CD45.2 mice. Flow cytometric analyses of nonparenchymal cells isolated from the livers of chimeric mice displayed that 45.9% of the
low

low

+

+

Ly6G/SiglecF Ly6C F-4/80 cells were CD45.1 . That finding was in line with the
results for non-parenchymal cells isolated from the livers of donor mice where 38.6% of
low

low

+

+

the Ly6G/SiglecF Ly6C F-4/80 cells were CD45.1 . In contrast, 36.5% of the
low

low

+

Ly6G/SiglecF Ly6C F-4/80 non-parenchymal cells isolated from the livers of recipient
+

mice were CD45.2 .

These data demonstrate that bone marrow transplantation in

lethally-irradiated and chlodronate-treated recipient mice results in the reconstitution of
kupffer cells in their livers from the transplanted cells (Fig. 6.13).
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Figure 6.13. Reconstituted kupffer cells in the livers of bone marrow recipient mice are derived from the
transplanted cells. Representative plots of flow cytometric analyses are showing that most of the live, non-parenchymal
and Ly6G/SiglecFlowLy6ClowF-4/80+ cells in the livers of (A) donor, (B) recipient and (C) chimeric mice were CD45.1+,
CD45.2+ and CD45.1+ respectively.
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Discussion
In chapter 5, the generalized involvement of gut microbiota in mediating NASH has
been demonstrated. Therefore, the next question to address is about the mechanism of
how gut microbiota contributes to the modulation of chronic inflammation on the grounds
of a fatty liver.

One important mechanism to associate gut microbiota with the

pathogenesis of diseases is the production of microbe-associated molecular patterns to
induce pro-inflammatory pathways through the interaction with pattern recognition
receptors mostly expressed by the innate cells [223].
Gut microbiota produces numerous types of microbe-associated molecular
patterns in the intestine that can enter the systemic circulation and induce inflammatory
responses through the interaction with their corresponding pattern recognition receptors
[224, 225]. Therefore, it is not possible to distinguish the pro-inflammatory capability of
individual microbe-associated molecular patterns when they are present together in the
system. In this study, we treated mice with broad spectrum antibiotics to diminish their
gut microbiota and then injected them with LPS, which allowed us to study the effect
solely mediated by this pro-inflammatory molecule without being affected by the
responses mediated by others.
TAK-242 is a small compound that selectively inhibits TLR-4 signaling through the
interference with interactions between TLR-4 and its adaptor molecules [226].
Therapeutic effect of TAK-242 was shown in mouse models of sepsis and endotoxinshock [227, 228]. It was also trialed for the treatment of severe sepsis in human [229].
To demonstrate the role of TLR-4 in the modulation of low grade LPS-mediated chronic
inflammation in the fatty liver, broad spectrum antibiotics/LPS-treated mice fed MD were
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injected with TAK-242 which blunted the inflammation induced by LPS. The outcome
from this experiment in mice promises TAK-242 as a potential therapeutic option for
NASH in human. Therefore, it could be used for clinical trial as a NASH drug in future.
Noticeably, administration of TAK-242 in mice fed MD not only blunted the increase
in levels of pro-inflammatory indicators of NASH in LPS-injected mice fed MD, but also
reduced their levels lower than non LPS-injected control mice fed MD (Fig. 6.3-6.4). It
indicates a possibility that TAK-242 may interfere not only the LPS-TLR-4 pathway, but
also other pro-inflammatory pathways in NASH. Therefore, it could be a new topic of
study to investigate the role of TAK-242 in the inhibition of different pro-inflammatory
signaling in NASH.
Besides kupffer cells, other types of cells in the liver e.g. hepatocytes, sinusoidal
endothelial cells, stellate cells, and hepatic dendritic cells, are also known to express TLR4 [230, 231].

Therefore, the sole contribution of TLR-4-expressing kupffer cells in

mediating NASH had remained unclear. To address this question, kupffer cells in wildtype mice were reconstituted by TLR-4 KO kupffer cells and kupffer cells in TLR-4 KO
mice were reconstituted by wild-type kupffer cells through bone marrow transplantation.
After induction of NASH, wild-type mice containing TLR-4 KO kupffer cells showed a
reduced level of NASH as compared to the wild-type mice containing wild-type kupffer
cells. On the other hand, TLR-4 KO mice containing wild-type kupffer cells displayed an
elevated level of NASH as compared to the TLR-4 KO mice containing TLR-4 KO kupffer
cells. Thus, our experiment clarified the essential role of TLR-4-expressing kupffer cells
in mediating NASH.
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Chapter 7
Peroxisomal Structure and Anti-oxidative Function is Compromised in
NASH in a TLR-4 Dependent Manner
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Summary
Peroxisomes are one of the major sites for the generation and decomposition of
reactive oxygen species (ROS), in particular hydrogen peroxide (H2O2). Catalase is the
H2O2-decomposing enzyme exclusively localized in peroxisomes. Catalase detoxifies
H2O2 produced not only in peroxisomes but also in mitochondria through peroxisomemitochondria communication. Therefore, a compromised peroxisomal structure and
function can lead to the accumulation of H2O2 that can exacerbate oxidative stress and
inflammation. Sublethal dose of endotoxin in rat was reported to induce structural and
functional alterations in liver peroxisomes which led us to investigate the role of TLR-4
pathway in mediating any alteration in peroxisomal structure and anti-oxidative function
in the steatotic livers of mice. Fluorescent Immunohistochemistry of peroxisomal
membrane protein 70 (PMP70) and catalase in the liver sections of mice fed MD displayed
a reduced level of immunofluorescence intensity, when compared to the mice fed control
diet, indicating an altered peroxisomal structure and anti-oxidative function respectively.
Fluorescence intensity of immuno-stained PMP70 and catalase significantly increased in
the livers of TLR-4 KO mice fed MD, when compared to the wild-type mice fed MD,
indicating that alteration of peroxisomal structure and anti-oxidative function in NASH is
dependent on TLR-4 pathway. Catalase activity assay using tissue homogenates from
mice fed MD demonstrated a reduced level of catalase activity, as compared to the mice
fed CD, which increased in TLR-4 KO mice fed MD. These data indicated that TLR-4
pathway mediates an alteration in peroxisomal structure and anti-oxidative function in
NASH. Thus, our study provides a new insight into the pathophysiological mechanism of
how TLR-4 pathway contributes to the pathogenesis of NASH.
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Introduction
Peroxisomes are essential subcellular organelles which are ubiquitous in
eukaryotic cells [232]. They have indispensable role in the synthesis of bile acids, myelin
lipid plasmalogens, and docosahexaenoic acids and catabolism of long-chain fatty acids,
very-long-chain fatty acids, and branched-chain fatty acids through a set of α and βoxidation reactions [232-234]. Apart from lipid catabolism, peroxisomes are also involved
in degradation of polyamines, glyoxylate, certain amino acids, arachidonic acids, and
several xenobiotics [234]. In addition, peroxisomes are also involved in generation and
scavenging of reactive oxygen species (ROS) produced inside and outside this organelle
[235].

Thus, peroxisomes play an important role in cell metabolism and metabolic

homeostasis through communication with other organelles especially mitochondria [236].
Critical metabolic role of peroxisome is closely associated with the exertion of control over
inflammatory responses. Peroxisomes exert control over inflammation in three different
ways. First, degradation of pro-inflammatory arachidonic acids; second, synthesis of antiinflammatory docosahexaenoic acids; and third, scavenging of ROS.
One important catabolic function of peroxisome is the degradation of arachidonic
acid derivatives known as eicosanoids.

Commonly known eicosanoids are

prostaglandins, thromboxanes, leukotrienes, and prostacyclins which have tremendous
role in the elicitation of broad ranging inflammatory responses. Most important proinflammatory activities mediated by these molecules are vasodilation/vasoconstriction,
leukocyte migration and platelet aggregation [237, 238].
Peroxisomes

contain

enzymes

which

contribute

to

the

synthesis

of

docosahexaenoic acids. Docosahexaenoic acids are peroxisomally produced omega-3
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fatty acids used as precursors for resolvins, maresins and protectins. These molecules
possess potent anti-inflammatory and immunoregulatory functions [239-241].
Peroxisomes play a dual role in generation and detoxification of ROS particularly
hydrogen peroxide (H2O2). Peroxisomes contain different oxidases that generate H2O2
as a byproduct of their oxidation reactions. These oxidases are co-localized with catalase
which is exclusively found in peroxisomes. Catalase decomposes H2O2 into H2O and
molecular oxygen [242]. Catalase scavenges H2O2 generated not only in peroxisomes
but also in extra-peroxisomal sites like mitochondria. Peroxisomes and mitochondria can
exchange their metabolites including H2O2 through intra-organellar diffusion, vesicular
traffic or direct physical contact [236].

Therefore, depending on the abundance of

peroxisomes within the cells and their catalase content, they can efficiently detoxify
cellular H2O2 generated within the cells during the metabolic reactions [232, 233, 243].
Impaired detoxification of H2O2 by peroxisomes due to their structural and functional
alterations in an inflamed milieu can result in an increased level of oxidative stress and
thereby exacerbate the inflammation [235].
Liver is the key metabolic organ which governs the energy balance of the body
[244]. Peroxisomes are most abundant in hepatocytes where they constitute round 1-2%
of the total cell volume [245]. Thus, peroxisomes play the major role in the neutralization
of bulk amount of H2O2 continuously produced in this metabolically active organ. Hepatic
steatosis results in enhanced production of H2O2 making the organ more dependent on
peroxisomes for safe disposal of H2O2 [246]. Therefore, there is a concern about any
impairment in peroxisomal function that can potentially exacerbate the oxidative stress in
the steatotic liver and facilitate the progression of the disease to NASH.
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Knowledge about an impaired peroxisomal function in NASH first came from the
observation that homozygous mutation of the peroxisome proliferator-activated receptorα gene (PPAR-α), the key regulator of genes involved in peroxisomal proliferation,
accumulate fat in the liver of mice under a starved condition [247].

Subsequent study

showed that acyl-coenzyme A oxidase null mice, the rate limiting enzyme for peroxisomal
β-oxidation, leads to the development of NASH, further indicating the role of impaired
peroxisomal function in mediating NASH [248]. Therefore, we anticipated that there
occurs an impairment in peroxisomal structure and antioxidative function in dietary fat
mediated NASH. It was reported that intraperitoneal injection of sublethal dose of LPS in
rat alters the structure, number, and function of peroxisomes [249, 250].

Elevated

expression of TLR-4 in the steatotic liver has been associated with the increased
sensitivity to gut-derived LPS resulting in chronic inflammation [251, 252]. Therefore, in
this current study, we examined the effect of TLR-4 pathway on peroxisomal structure
and antioxidative function in the modulation of NASH in mice fed MD.
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Results
Peroxisomal structure is altered in the livers of mice fed MD in a TLR-4 dependent
manner
Fluorescence immunohistochemistry of PMP70, a major component of
peroxisomal membrane [253], in the liver sections of mice fed MD demonstrated a
decreased fluorescence intensity as compared to the mice fed CD. In the same time,
immunofluorescence-stained liver sections of TLR-4 KO mice fed MD displayed an
increased level of fluorescence intensity than WT mice fed MD (Fig. 7.1). This data
indicated that peroxisomal structure is altered in mice fed MD in a TLR-4-dependent
manner.
Catalase level and activity are decreased in the livers of mice fed MD in a TLR-4
dependent manner
An alteration in peroxisomal structure led us to investigate the plausible change in
peroxisomal antioxidative function. Fluorescence immunohistochemistry of catalase, a
major antioxidative enzyme exclusively found in peroxisomes, in the liver sections of mice
fed MD demonstrated a decreased fluorescence intensity as compared to the mice fed
CD. In the same time, immunofluorescence-stained liver sections of TLR-4 KO mice fed
MD displayed an increased level of fluorescence intensity than WT mice fed MD (Fig.
7.2). This data indicated that catalase level is altered in mice fed MD in a TLR-4dependent manner.
Western blot analysis demonstrated a decreased level of catalase in the livers of
wild-type mice fed MD as compared to the wild-type mice fed CD. In the same time,
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Catalase level was increased in TLR-4 KO mice fed MD (Fig. 7.3A-B). This data indicated
that the level of catalase in mice fed MD is decreased in a TLR-4 dependent manner
which was consistent with the observation in fluorescence immunohistochemistry of
catalase. Of note, catalase level was also increased in TLR-4 KO mice fed CD compared
to the WT mice fed CD. This indicated the catalase level is very sensitive to the basal
activity of TLR-4 pathway.
Catalase activity assay was performed using liver tissue homogenates. Catalase
activity was decreased in wild-type mice fed MD as compared to the wild-type mice fed
CD. Catalase activity significantly increased in TLR-4 KO mice fed MD as compared to
the wild-type mice fed MD indicating the role of TLR-4 pathway-mediated chronic
inflammation on catalase activity in NASH (Fig. 7.3C). Catalase activity data was
consistent with the level of catalase displayed by fluorescence immunohistochemistry and
Western blot analysis.
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Figure 7.1. Fluorescence immunohistochemistry of peroxisomal membrane protein 70 in liver sections
displayed a reduced level of fluorescence intensity in mice fed milk-based high fat diet in a TLR-4
dependent manner. Immunofluorescence staining of peroxisomal membrane protein 70 in liver sections
displayed a reduced level of fluorescence intensity in WT mice fed MD as compared to the WT mice fed CD.
Fluorescence intensity increased in TLR-4 KO mice fed MD as compared to the WT mice fed MD. CD and MD
denote control diet and milk-based high fat diet, respectively.
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Figure 7.2. Fluorescence immunohistochemistry of catalase in liver sections displayed a reduced level
of fluorescence intensity in mice fed milk-based high fat diet in a TLR-4 dependent manner.
Immunofluorescence staining of catalase in liver sections displayed a reduced level of fluorescence intensity in
WT mice fed MD as compared to the WT mice fed CD. Fluorescence intensity increased in TLR-4 KO mice fed
MD as compared to the WT mice fed MD. CD and MD denote control diet and milk-based high fat diet,
respectively.
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A

B

C

Figure 7.3. Catalase level and activity are decreased in the livers of mice fed milk-based high fat diet which
is dependent on TLR-4. Catalase level and activity were decreased in the livers of mice fed MD as compared to the
mice fed CD in TLR-4 dependent manner as shown by (A) Western blot analysis (B) Image J analysis of the Western
blot image and (C) catalase activity assay. CD and MD denote control diet and milk-based high fat diet, respectively.
*P<0.05, **P<0.01 (Man-Whitney test); data are expressed as mean±SEM; n=3-6.
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Discussion
Reactive oxygen species (ROS) are endogenously produced as byproducts of
cellular metabolic processes in mitochondria and peroxisomes [254, 255]. Cellular
homeostasis mediated by anti-oxidant defense system prevents the accumulation of ROS
within the cells. When the level of ROS overwhelms the anti-oxidant defense system,
whether through an excessive production of ROS or a reduction of anti-oxidant defense
capacity, oxidative stress occurs [256]. A sustained oxidative stress can lead to chronic
inflammation which can potentially serve as a cause of different advanced stage diseases
[257, 258].
Peroxisomes are single membrane-bounded ubiquitous organelles in eukaryotic
cells [255]. Several metabolic processes, including catalase-mediated detoxification of
H2O2, exclusively occurr in peroxisomes [259]. The number, morphology, and activity of
peroxisomes can remarkably vary depending on the tissue, organ, and nutritional and
metabolic status [236]. Peroxisomes produce different ROS from different metabolic
pathways that are neutralized by enzymatic and non-enzymatic anti-oxidant defense
systems. Catalase is a unique member of peroxisomal anti-oxidant defense system
which neutralizes H2O2 in a catalytic (2 H2O2 → 2 H2O + O2) or peroxidatic
(H2O2 + AH2 → A + 2 H2O) manner [259]. Although catalase is localized exclusively
within peroxisomes, they can decompose H2O2 produced not only in peroxisomes but also
in extra-peroxisomal sites such as mitochondria through inter-organellar exchange of
metabolites [236]. Thus, catalase-mediated detoxification of H2O2 in peroxisomes plays
an indispensable role in preventing the cell from reaching the stage of oxidative stress.
Besides catalase, peroxisomes are also required for the biosynthesis of plasmalogens.
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Plasmalogens are ether-phospholipids known to have anti-oxidative function, but it is still
unclear how much role they play in providing anti-oxidative defense [260].
Oxidative stress is the key mediator of NASH, which is caused by the increased
availability of free fatty acids in the steatotic livers [261, 262]. Therefore, NASH-affected
livers are in increased demand of anti-oxidative mediators. Impaired detoxification of
H2O2 in NASH-affected livers due to any alteration in peroxisomal structure and function
may exacerbate the severity of the disease. In this study, we have shown that the
catalase level and activity decrease in the livers of mice model of NASH which are
reversed in TLR-4 KO mice indicating the role of TLR-4 pathway in the modulation of antioxidative function of catalase. It may be due to the adverse effect of TLR-4 pathwaymediated low grade chronic inflammation on the structure and/or function of peroxisomes
in the fatty liver. Not only in TLR-4 KO mice fed MD, we have also observed an increase
in catalase level and activity in the livers of TLR-4 KO mice fed CD as compared to the
wild-type mice fed CD. It might be due to the sensitivity of peroxisomal structure and
function to the basal activation of TLR-4.
The findings presented in this study are in line with previous reports demonstrating
the role of endotoxin-induced inflammation in alteration of peroxisomal structure-function
in the liver [249, 250]. Endotoxin-induced inflammation causes change in lipid
composition of peroxisomes in the liver [250]. Because the concentration of circulating
endotoxin is increased in NASH, it is important to know how the lipid composition of
peroxisomes are affected in NASH. Besides endotoxin-induced inflammation, increased
concentration of free fatty acids is also an important contributor to organelle malfunction.
Increased concentration of free fatty acids alters the lipid composition in mitochondria and
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endoplasmic reticulum, resulting in their impaired function [263, 264]. Because fat
accumulation in the liver results in an increased concentration of free fatty acids, it
demands a comprehensive study to determine the changes in structural composition of
peroxisomes to have a clearer picture on their impaired anti-oxidative function in NASH.
TLR-4 pathway-mediated alteration of peroxisomal structure/function in NASH may not
only reduce their anti-oxidative activity but also impact the peroxisome-mediated
synthesis of anti-inflammatory and degradation of pro-inflammatory molecules.
Therefore, it requires a further investigation to study the effect of TLR-4 pathway on the
peroxisomal metabolism of different pro and anti-inflammatory molecules potentially
associated with NASH.
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Chapter 8
Conclusions and Overall Discussion
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Because chronic inflammation is the principal reason for the progression of a
benign fatty liver into an end stage disease, the ultimate goal of all NASH research is to
stop the inflammation. To stop the inflammation in the fatty liver, it is urgent to reduce the
availability of causative agents of inflammation, or therapeutically interfere with their
signaling pathways. In this project, gut microbiota has been studied as a potential source
of pro-inflammatory agents of NASH. We have comprehensively investigated the role of
the gut microbiota-derived LPS-TLR-4 pathway as a potential mediator of NASH with
therapeutic relevance, using an appropriate experimental model.
Study of NASH in mice fed high fat diet represents a clinically relevant model
When compared to other genetic and diet-based models of NASH, high fat diets
are clinically more relevant for some genuine reasons. First, high fat diets do not contain
any ingredient that is unusual in the regular human diet. In fact, high fat diets are prepared
from sources that are commonly consumed by humans, e.g., vegetable oil, coconut oil,
milk fat, beef tallow, lard and other sources [265]. Second, high fat diets mimic western
diets in having high fat content [266]. Third, high fat diets induce the development of
NASH spontaneously without requiring any additional dietary intervention [150]. When
compared to other dietary models, high fat diets require a longer period of feeding to
induce NASH. For instance, a methionine and choline deficient diet induces NASH at
day 10 of feeding, whereas a high fat diet requires 8-12 weeks [133, 142, 150, 267]. This
requirement of long-term feeding is consistent with NASH patients requiring a long period
of pathogenesis [150]. Finally, high fat diets result in the development of obesity and
NASH simultaneously, which is a common scenario in the case of NASH patients [150].
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Therefore, high fat diets offer an opportunity to study NASH within the context of metabolic
syndrome, which is known to manifest as NAFLD in the liver.
Both unsaturated and saturated fats are present in regular human diets [157]. The
role of saturated fats in inducing steatosis and chronic inflammation in the liver has been
demonstrated in numerous reports [160-163]. In line with those findings, we designed a
comparisonal study between a milk-based saturated high fat diet and a lard-based
saturated diet, thus demonstrating the higher efficiency of a milk-based saturated high fat
diet over a lard-based unsaturated high fat diet in inducing NASH. We also performed an
experiment where mice were fed at three different time points (8, 16 or 32 weeks)
resulting in a significantly higher level of NASH at weeks 16 and 32, as compared to
week 8. Based on these results, we fed mice with a milk-based saturated high fat diet for
16 weeks to ensure a maximum level of steatosis and inflammation in the remaining
experiments of the study.
To keep our animal study consistent with human patients, it was important to
evaluate the level of disease with methods similarly used for diagnostic purposes in
humans. We used both noninvasive and invasive methods to detect and measure the
level of NASH in mice. In the case of human patients, noninvasive methods are of first
preference. Imaging techniques, e.g., ultrasonography, computerized tomography, and
magnetic resonance imaging are widely used noninvasive methods to identify fat
deposition in the liver. One major limitation of those imaging methods is that they cannot
distinguish steatosis from NASH [268-271]. Therefore, imaging methods were of no use
in our NASH study on animal models. Assays employed for determining ALT and AST
activities in serum are also commonly used noninvasive methods of NASH diagnosis.
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Elevated levels of ALT and AST activity in serum indicates hepatocyte damage
subsequent to hepatic inflammation. Those levels can rise up to five fold in NASH
patients compared to their upper limits in healthy individuals. Although ALT and AST
activity in serum cannot give an accurate indication about the degree or severity of liver
disease, those markers were used as an important indicator of NASH in our study [268,
272, 273]. Apart from those noninvasive methods, liver biopsy is the most reliable
invasive technique to diagnose NASH. Biopsy samples are used for histology that can
diagnose as well as evaluate the level of disease. Biopsy sections are evaluated based
on steatosis, inflammation, hepatocyte ballooning, necrosis, and fibrosis. Yet liver
histology is a controversial tool to diagnose NASH in humans due to the risks of biopsy
and the validity of a tiny biopsy for representing NASH in the entire liver [272, 274]. Due
to the availability of tissue post euthanization, liver histology is an unquestionably useful
method for disease evaluation in animal models of NASH.

Thus, because of the

application of different, clinically used noninvasive and invasive indicators of NASH, our
study outcome has strong clinical relevance.
Gut microbiota spans gut-liver axis in causing NASH
In this project, we also studied the role of gut microbiota in mediating NASH. We
found a reduced level of dietary fat-mediated chronic inflammation in the livers of mice
that were germ free or treated with broad spectrum antibiotics, as compared to control
mice. Mechanisms explaining the communication between the gut microbiota and NASH
are still widely investigated. A large body of evidence from both population and animal
studies clearly indicates that changes in the composition of gut microbiota are closely
associated with NASH. One widely studied mechanism of gut microbiota in inducing
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NASH is altered production of metabolites. For instance, changes in gut microbiota of
NASH patients result in higher abundance of Escherichia and increase the level of
endogenous alcohol in the circulation, leading to the increased production of ROS in the
liver [275, 276]. Another important metabolic role of gut microbiota is the production of
short chain fatty acids, which provide nutrients and energy essential for maintaining gut
health and integrity. An altered production of short chain fatty acids results in defective
gut permeability, leading to an increase of pro-inflammatory microbial elements in the
portal circulation [277]. Gut microbiota also has an important role in the regulation of
intestinal lipid absorption mediated by the deconjugation of bile acids in intestine.
Deconjugation of bile acids is mediated by the removal of polar groups of
glycine and taurine catalyzed by gut microbial enzymes. Impaired deconjugation of bile
acids can lead to increased emulsification and absorption of dietary fat, resulting in
hepatic steatosis [277, 278]. It is still not clear whether the abundance of microbes
expressing the enzymes associated with bile acid deconjugation is altered in NASH.
Apart from their metabolic functions, the supply of pro-inflammatory microbesassociated molecular patterns into the liver is also a potential mechanism of gut
microbiota in mediating NASH.

Prominent microbes-associated molecular patterns

involved in NASH include endotoxin, peptidoglycan, flagellin, and microbial nucleic acids
[279]. In this comprehensive study, we demonstrated the role of gut-derived LPS in
mediating NASH through the TLR-4 receptor.
Gut microbial community gets changed in NASH
The role of specific microbes has been reported to induce different inflammatory
diseases in mice fed a high fat diet. A milk-based saturated fat diet can induce colitis in
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IL10-/- mice through the expansion of Bilophila wadsworthia [159]. The Enterobacter
cloacae B29 strain isolated from the gut of an obese human has been shown to induce
obesity and insulin resistance in germ free C57BL/6J mice fed a high fat diet, whereas
germ free control mice on a high-fat diet were protected from disease phenotypes [280].
Our current project revealed an overall change in the structure of gut microbial community
in mice fed MD, but we could not identify a specific microbe associated with NASH.
Therefore, it is important to undertake a future investigation to identify microbes whose
presence could be directly related to the pathogenesis of NASH.
Feeding mice with a high fat diet has been reported to result in increased
concentration of circulating endotoxin [122, 123]. Consistent with those reports, we have
shown a trend of higher concentration of endotoxin in the portal serum of mice fed MD,
as compared to the mice fed CD.

Those data led us to investigate whether the

composition of gut microbiota is changes, resulting in an increased abundance of Gram
negative bacteria in mice fed MD. However, our 16s rRNA analysis displayed a decrease
in the relative abundance of Bacteroidetes, the major Gram negative phylum in gut
microbiota in mice [281]. Yet the relative abundance of Proteobacteria, another important
Gram negative phylum in the gut microbiota of mice, was significantly increased [282].
Further investigation is required to determine if the entire phylum of Proteobacteria or any
specific microbe within the phylum, plays a key role in mediating chronic endotoxemia in
mice fed MD.
Altered gut permeability facilitates the elevation of circulating endotoxin level
The

elevated

concentration

of

gut

microbiota-derived

pro-inflammatory

components in the circulation of NASH patients, especially endotoxin, is mediated by
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increased gut permeability [283, 284]. However, a comprehensive assessment in an
animal model is yet to be performed in order to explain the relationship between gut
permeability and NASH. In the case of obesity, an increased level of TNF-α in the serum
has been associated with inflammation in the intestine leading to gut leakage [285]. In
our study, a higher level of expression of TNF-α was observed in the livers of NASHaffected mice. Therefore, it is possible that an increased production of TNF-α in the
altered cytokine milieu of NASH eventually leads to the inflammation in intestine.
Additionally, changes in gut microbiota in NASH may also alter intestinal permeability
through the pathways driven by bacterial metabolites. Zhu and colleagues reported that
expression of alcohol-metabolizing enzymes are up-regulated in NASH livers [276]. In a
follow-up study, they reported that the abundance of alcohol-producing Escherichia is
increased in the gut of NASH patients as compared to non-obese and obese non-NASH
controls, leading to an elevated concentration of alcohol in the blood serum of NASH
patients [275]. Gut microbiota-produced alcohol is known to have a potential role in
increasing gut permeability [286] and the generation of reactive oxygen species in the
liver [287]. Thus, gut permeability and NASH participate in a positive feedback loop in
causing the disease. In our animal study, Clostridium was the only alcohol-producing
genus whose abundance was increased in the gut microbiota of NASH.

Further

investigation is required to determine the extent to which Clostridium contributes to the
mediation of gut permeability.
LPS-TLR-4 pathway plays an essential role in mediating NASH
Using a unique approach, we studied the role of LPS in causing NASH through the
injection of LPS in mice treated with broad spectrum antibiotics. The purpose of LPS
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injection in broad spectrum antibiotics-treated mice was to ensure the presence of LPS
in the system as the sole pro-inflammatory agent derived from microbes. Therefore, the
TLR-4-mediated inflammation in the fatty liver was attributed only to LPS, not to any other
microbial agents. Apart from microbes-derived LPS, there are many endogenous hostderived ligands of TLR-4 with varying activation potential, e.g., low-molecular weight
hyaluronic acid, heparin sulfate, saturated fatty acid, fibrinogen, fibronectin, heat shock
proteins 60 and 70, high mobility group box-1, and degraded matrix [288]. It is still not
clear what level of TLR-4 activation is contributed by these endogenous ligands.
The level of TLR-4 pathway activation can vary depending on the types of LPS.
Acylation of lipid A, the actual site of LPS recognized by TLR-4, can vary in terms of
number, length, and saturation level of fatty acyl chains [289]. While human TLR-4 can
sense only hexaacyl lipid A, murine TLR-4 can sense pentaacyl or tetraacyl lipid A [290].
Furthermore, lipid A attached with saturated fatty acyl chains with lengths of 12 or 14 (or
occasionally 16) are better agonists of TLR-4 [291]. In the complex ecology of gut
microbiota, LPS molecules with different types of lipid A are produced. Therefore, it is
important to investigate whether the altered gut microbiota in the mice fed a high fat diet
produce higher levels of those types of LPS, which are stronger agonists of TLR-4.
TLR-4 pathway is a promising target for therapeutic intervention against NASH and
ischemia/reperfusion injury in liver transplantation
High fat diet-mediated hepatic steatosis in TLR-4 KO mice displayed a reduced
level of inflammation as compared to the wild-type mice; even the chronic administration
of low dose LPS could not increase the level of inflammation in the fatty liver of TLR-4 KO
mice. Those data demonstrated the prospect of TLR-4 pathway as a therapeutic target
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for the treatment of NASH. In our study, we administered TAK-242, an inhibitor of TLR4, in LPS-injected mice fed a high fat diet, resulting in a significant decrease in the levels
of NASH-indicative markers. TAK-242, a novel synthetic molecule with the chemical
name resatorvid, suppresses TLR-4 signaling by selectively binding to the TIR domain
via Cys747 [292-294]. Although several studies have reported the protective role of TAK242 against acute inflammation in different disease conditions, it is still not clear how
efficient TAK-242 may be in inhibiting chronic inflammation. TAK-242 has demonstrated
protective effects against Escherichia coli-induced sepsis and acute endotoxemic shock
in mice [227, 228]. Most importantly, TAK-242 has been tested on a trial to treat severe
sepsis in human patients [229]. The findings from studies on TLR-4-miediated acute
inflammation indicate a plausible role for TAK-242 in inhibiting TLR-4-induced chronic
inflammation. Thus, in our study, data on the protective role of TAK-242 against NASH
in mice offer therapeutic promise for the treatment of NASH in human patients.
The TLR-4 pathway has been correlated not only with chronic inflammation in
NASH, but also with warm ischemia/reperfusion injury in liver transplantation [295].
Circulating endotoxin is a critical factor in causing injury in the liver following
ischemia/reperfusion. Steatotic livers are more sensitive to endotoxin in developing
ischemia/reperfusion injury compared to their lean counterparts [296].

Our lab has

reported that the neutralization of endotoxins through treatment with anti-endotoxin
monoclonal antibody

dramatically improved survival rate and liver function after

ischemia/reperfusion injury in mice with hepatic steatosis [297]. We also reported that
deficiency of TLR4 is protective against ischemia/reperfusion injury in the mouse steatotic
liver [296]. Therefore, we anticipate that inhibition of the TLR-4 pathway through the
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treatment with TAK-242 would be protective against ischemia/reperfusion injury in
steatotic liver.
Therapeutic interference of LPS-TLR-4 pathway may improve hepatic regeneration
following partial hepatectomy in steatotic liver
We have studied the impact of dietary fat mediated NASH in the impairment of
hepatic regeneration following partial hepatectomy. No study has yet investigated the
role of gut microbiota or the role of the LPS-TLR-4 pathway in modulating the impairment
of hepatic regeneration following partial hepatectomy in the steatotic liver. Such a study
could result in a novel drug with therapeutic potential for the treatment of impaired hepatic
regeneration in NASH. In this project, we have shown that the TLR-4 inhibitor, TAK-242,
can suppress chronic inflammation in the fatty liver. Therefore, treatment of mice with
TAK-242 before surgical resection is anticipated to inhibit the pro-inflammatory insult on
the regenerating lobes of the liver and thereby improve impaired regeneration. It has also
been demonstrated in this project that diminishing of gut microbiota through treatment
with broad spectrum antibiotics results in a reduced concentration of serum endotoxin
and a decreased level of NASH. Therefore, treatment of mice with broad spectrum
antibiotics before partial hepatectomy surgery is anticipated to result in an improved
regeneration outcome.
A published study from our lab demonstrated that pre-treatment of obese mice
(ob/ob) with anti-endotoxin monoclonal antibodies could protect them from subsequent
hepatic ischemia/reperfusion injury, indicating the role of circulating endotoxin in
mediating the inflammatory cascade in the steatotic liver [298]. Therefore, pretreatment
of mice with anti-endotoxin monoclonal antibodies prior to partial hepatectomy could
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potentially reduce the level of inflammation by sequestering the endotoxins from binding
to Kupffer cells, thereby ameliorating hepatic regeneration.
Why peroxisomes are important in controlling oxidative stress
In mammals, peroxisomes play an indispensable role in numerous metabolic
pathways including fatty acid α- and β-oxidation. During those metabolic processes,
peroxisomes produce a bulk amount of ROS as byproducts of different biochemical
reactions that are efficiently neutralized, using a set of enzymatic and non-enzymatic
defense mechanisms [236]. Except for catalase, most of those anti-oxidant defense
mechanisms are common in other metabolically active organelles, especially
mitochondria [242]. Catalase is the H2O2-detoxifying enzyme in the cell [299]. Catalase
is exclusively localized in peroxisomes, but H2O2 is generated in both peroxisomes and
mitochondria. In fact, only 35% of H2O2 within the cell is generated by peroxisomes in the
rat liver [242]. H2O2 generated in mitochondria is also decomposed by peroxisomal
catalase, which is mediated by peroxisome-mitochondrial communication [236].
Therefore, peroxisomes play a major role in controlling oxidative stress by preventing the
accumulation of ROS.
Peroxisomal anti-oxidative function is impaired in NASH
Regular peroxisomal function in the healthy liver serves two important beneficial
roles simultaneously. One is the degradation of very long chain and branched-chain fatty
acids, thus preventing them from being accumulated in the liver to induce hepatic
steatosis; the other is the neutralization of ROS, preventing them from causing oxidative
stress [246, 300]. Up-regulation of peroxisomal biogenesis leads to a resistance to
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dietary fat-mediated hepatic steatosis in mice [301]. On the other hand, peroxisomedeficient mice develop an increased level of hepatic steatosis [302]. Recently, Park and
colleagues have reported that expression of peroxisomal proliferator-activated receptorα (PPAR-α), the master regulator of peroxisomal fatty acid oxidation and proliferation, is
reduced in methionine- and choline-deficient diet-induced NASH in mice [303]. They
have also shown that statin-mediated inhibition of hepatic steatosis and NASH recovers
the expression level of PPAR-α. Those data indicate an impaired peroxisomal function
in NASH that is consistent with the reduced catalase level and activity demonstrated in
the livers of mice fed MD in our study. It is still not clear if the decreased level and activity
of catalase in NASH is due to the reduced biogenesis or structural alteration of
peroxisomes.
Intervention of TLR-4 pathway can improve peroxisomal anti-oxidative function
In this project, we have demonstrated that the catalase level and function increase
in TLR-4 KO mice fed MD as compared to the wild-type mice fed MD, indicating an
important role for the TLR-4 pathway in regulating peroxisomal function in NASH. The
impact of the TLR-4 pathway on peroxisomal function might be mediated in two different
ways: a) alteration of peroxisomal structure as a direct influence of pro-inflammatory
milieu, and b) cross-talk between the TLR-4 pathway and the biogenesis of peroxisomes,
leading to their reduced proliferation. The impact of the TLR-4 pathway in the alteration
of peroxisomal structure has been indicated in studies by Khan and colleagues [249, 250].
They have shown that administration of a sub-lethal dose of endotoxin induces changes
in peroxisomal structure and function in the rat liver.
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Possible crosstalk between the TLR-4 pathway and peroxisomal biogenesis has
been indicated in a study by Necela and colleagues [304]. They have shown that
activation of the TLR-4 pathway leads to the downregulation of peroxisomal proliferatoractivated

receptor-γ

(PPAR-γ)

through

an

NF-κB-dependent

mechanism

in

macrophages. They have also shown that knockout of PPAR-γ results in an increased
expression of pro-inflammatory genes, indicating a regulatory feedback loop between
TLR-4 pathway and expression of PPAR-γ.

Because PPAR-α and PPAR-γ share

similarity in their ligands and mechanism of inducing gene expression [305], the existence
of similar type of regulatory feedback loop between TLR-4 and PPAR-α cannot be ruled
out. Because PPAR-α is the key transcription factor in the PPAR family that regulates
the expression of genes involved in peroxisomal β-oxidation and proliferation, it is
important to investigate a potential crosstalk between TLR-4 and PPAR-α.
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